CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
NANOPARTICLE FORMULATIONS WITH
ENHANCED MUCOSAL PENETRATION
FIELD OF THE INVENTION
This invention is in the field of nanoparticle formulations,
particularly hypotonic nanoparticle formulations that rapidly deliver mucus-
penetrating nanoparticles to mucosal covered epithelial surfaces, and
methods of making and using thereof.
GOVERNMENT RIGHTS
The United States government has certain rights in this invention.
This work was supported by National Institutes of Health grants
R01HD062844, R33A1079740, R01CA140746) (ill, and R.C.), the National
Science Foundation (L.M.E. and the National Institutes of Health/
Microbicide Innovation Program 5R21A1079740.
PRIORITY CLAIMS
U.S.S.N. 61/588,350 filed January 19, 2012
PCT/US2012/024344 filed February 8, 2012
PCT/US2012/069882 filed December 14, 2012
BACKGROUND OF THE INVENTION
Localized delivery of therapeutics via biodegradable nanoparticles
often provides advantages over systemic drug administration, including
reduced systemic side effects and controlled drug levels at target sites.
However, controlled drug delivery at mucosal surfaces has been limited by
the presence of the protective mucus layer.
Mucus is a viscoelastic gel that coats all exposed epithelial surfaces
not covered by skin, such as respiratory, gastrointestinal, nasopharyngeal,
and female reproductive tracts, and the surface of eye. Mucus efficiently
traps conventional particulate drug delivery systems via steric and/or
adhesive interactions. As a result of mucus turnover, most therapeutics
delivered locally to mucosal surfaces suffer from poor retention and
distribution, which limits their efficacy.
Drug and gene carrying nanoparticles delivered to mucus-covered
cells in the eyes, nose, lungs, gastrointestinal tract, and female
reproductive
1
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
tract must achieve uniform distribution in order to maximally treat or protect
these surfaces. However, the highly viscoelastic (i.e., viscous and solid-like
in nature) and adhesive mucus layer can slow or completely immobilize
particles, and thereby prevent them from spreading over the mucosal surface.
In addition, some mucosal surfaces, such as those of the mouth, stomach,
intestines, colon, and vagina, exhibit highly folded epithelial surfaces that
are
inaccessible to conventional muco-adhesive particles and also to many small
molecule drugs and therapeutics. Without maximal distribution with
penetration into these deep recesses, much of the epithelium is left
susceptible and/or untreated. Additionally, penetration into the folds,
presumably containing a much more slowly cleared mucus layer, allows for
increased residence time at the epithelial surface.
For drug or gene delivery applications, therapeutic particles must be
able to 1) achieve uniform distribution over the mucosal surface of interest,
as well as 2) cross the mucus barrier efficiently to avoid rapid mucus
clearance and ensure effective delivery of their therapeutic payload to
underlying cells (das Neves .1 & Bahia MF IntJPharm 318, 1-14 (2006); Lai
et al. Adv Drug Deliver Rev 61, 158-171(2009); Ensign et al. Sci Transl
Med 4, 138ra179 (2012); Eyles et al. J Pharm Pharmacol 47, 561-565
(1995)).
Biodegradable nanoparticles that penetrate deep into the mucus
barrier can provide improved drug distribution, retention and efficacy at
mucosal surfaces. Dense surface coats of low molecular weight polyethylene
glycol (PEG) allow nanoparticles to rapidly penetrate through highly
viscoelastic human and animal mucus secretions. The hydrophilic and
bioinert PEG coating effectively minimizes adhesive interactions between
nanoparticles and mucus constituents. Biodegradable mucus-penetrating
particles (MPPs) have been prepared by physical adsorption of certain
PLURONICs, such as F127, onto pre-fabricated mucoadhesive
nanoparticles.
The surface of the vagina is highly folded to accommodate expansion
during intercourse and childbirth; these folds, or "rugae," are normally
collapsed by intra-abdominal pressure, hindering drug delivery to the folded
2
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
surfaces. For truly effective prevention and treatment, sustained drug
concentrations must be delivered to, and maintained over the entire
susceptible surface. Failure to achieve adequate distribution over the entire
vaginal epithelium is a documented failure mode of vaginal microbicides.
Another significant barrier to effective drug delivery to the vagina is
the viscoelastic layer of mucus secreted by the endocervix that coats the
vaginal epithelium. Mucus efficiently traps foreign particles and particulates
by both steric and adhesive mechanisms, facilitating rapid clearance.
Although the use of mucoadhesive dosage forms has been proposed for
increasing residence time in the vagina, mucus clearance occurs rapidly (on
the order of minutes to hours), limiting the residence time of mucoadhesive
systems.
Mucosal epithelia use osmotic gradients to cause fluid absorption and
secretion. Vaginal products have traditionally been made with hypertonic
formulations, including yeast infection treatments, most sexual lubricants
such as KY warming gel, and gels designed for preventing sexually
transmitted infections such as HIV. Hypertonic formulations cause rapid,
osmotically-driven secretion of fluid into the vagina, and this causes an
immediate increase in fluid leakage from the vagina at a rate proportional to
the hypeitonicity of the foimulation. Moreover, recent investigations of
candidate vaginal and rectal microbicides both in animal models and in
humans have revealed that hypertonic formulations cause toxic effects that
can increase susceptibility to infections. The first successful microbicide
trial for HIV prevention found that the antiretroviral drug, tenofovir,
delivered in a vaginal gel, provided partial protection. Unfortunately, the
gel
formulation was highly hypertonic, leading investigators in the most recent
clinical trial of tenofovir to reduce the concentration of glycerol to reduce
toxicity. However, the concentration was not reduced , and the formulation
is still significantly hypertonic. There appears to be no evidence to justify
hypertonic formulations for vaginal drug delivery, since in addition to the
documented toxic effects, hypertonic formulations cause rapid osmotically-
driven secretion of vaginal fluid, fluid flow that opposes the delivery of
drugs to the epithelium. This lack of justification has been ignored by both
3
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
investigators and manufacturers of vaginal products, the only evident
exception being sexual lubricants intended to support fertilization. These
products are formulated to be isotonic (the osmolality is equivalent to that
of
plasma) to help maintain viability of sperm.
Therefore, it is an object of the invention to provide formulations for
rapid and uniform particulate delivery of a wide range of drugs to mucosal
covered epithelial surfaces with minimal toxicity to the epithelium.
SUMMARY OF THE INVENTION
Osmosis can be used to cause rapid penetration of mucus-penetrating
particles into deep recesses in highly-folded mucosal tissues. Absorption
and penetrability into the deep recesses of mucosal tissues improves the
distribution over a mucosal surface of otherwise poorly distributed entities.
Rapid absorption and penetrability into deep recesses of mucosal tissues
leads to increased residence time of mucus-penetrating particles. Rapid
absorption facilitates user acceptability in addition to increasing the
effectiveness of the treatment and minimizing the time between application
and mucosal protection.
Hypotonic formulations were evaluated for delivering water-soluble
drugs and for drug delivery with muco-inert (that is, non-adhesive) mucus-
penetrating nanoparticles (MPP). Hypotonic formulations markedly
increased the rate at which drugs and MPP reached the epithelial surface.
Additionally, hypotonic formulations greatly enhanced drug and MPP
delivery to the entire epithelial surface, including deep into the vaginal
folds
(rugae) that isotonic formulations failed to reach. Hypotonic formulations
can cause free drugs not only to be drawn to the epithelium but also be drawn
through the epithelium, reducing vaginal retention. In contrast, hypotonic
formulations cause MPP to accumulate rapidly and uniformly on vaginal
surfaces, but they do not pass through the epithelium and thus remain ideally
positioned for sustained mucosal drug delivery. Minimally hypotonic
formulations, preferably ranging from 20-220 mOsmikg, provided rapid and
uniform delivery of MPP to the entire vaginal surface, with minimal risk of
epithelial toxicity. Hypotonic formulations for vaginal drug delivery via
4
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
MPP should significantly improve prevention and treatment of reproductive
tract diseases and disorders.
Data also show that there is a higher osmolality in the colon, such
that vehicles with an osmolality above that of blood plasma (generally
considered isotonic at ¨300 mOsm/kg), still lead to improvements in
distribution in the colon due to rapid, osmotically-induced fluid absorption.
The range for improved colon distribution with a hypotonic vehicle in the
colon is ¨20 mOsm/kg-450 mOsm/kg. In the preferred embodiment, the
formulation for application to the colon or rectum has an osmolality between
about 20 mOsm/kg and 450 mOsm/kg, wherein sodium ions (Na) cause at
least 30% of the osmolality in excess of 220 mOsm/kg. (i.e., if the
osmolality of the formulation is 450 mOsm/kg, Na ions must comprise at
least 30% to 450-220 --- 230 mOsim/kg, or 69 mOsm/kg). Improved
distribution of hypotonically administered MPP (compared to CP) on rectal
tissue with induced ulcerative colitis, including uptake of MPP into the
ulcerated tissue, was also demonstrated. Hypotonic administration also leads
to improved distribution of free drug (tenofovir labeled with FITC) in the
colon.
BRIEF DESCRIPTION OF THE DRAWINGS
Figures la and lb are representative trajectories of PLA-PEG and
PCL-PEG nanoparticles containing CHA and PVA prepared by an
emulsification method. Figures 1c and I d are graphs showing the ensemble-
averaged geometric mean square displacements (<MSD>/pm2) as function of
time (time scale/s). Figures le and If are graphs showing the penetrable
fraction as a function of distributions of the logarithms of individual
particle
effective diffusivities (Deff) at a time scale of 1 s. Figures lg and lh are
graphs showing the estimated fraction of particles capable of penetrating a
physiological 30um thick mucus layer over time. Data represent three
independent experiments with? 120 nanoparticles tracked for each
experiment. Error bars are presented as s.e.m.
Figures 2a and 2b show the effect of PEG MW on transport rate of
MPP in human cervicovaginal mucus: Figure 2a is a graph showing the
ensemble-averaged geometric mean square displacement <MSD/p.m2> as a
5
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
function of time scale/s. Figure 2b is a graph showing the distributions of
the logarithms of individual particle effective diffusivities (Deff) at a time
scale of 1 s. Particles were prepared with the emulsification method using
PLGA-PEG (6wt% PEG). Data represent three independent experiments
.with > 120 nanoparticles tracked for each experiment. Error bars are
presented as s.e.m.
Figure 3a is a graph showing the ensemble-averaged geometric mean
square displacement <MSD/ium2> as a function of time scale. Figure 3b is a
graph showing the distributions of the logarithms of individual particle
effective diffusivities (Derr) at a time scale of 1 s. Figure 3c is a graph
showing the estimated fraction of particles predicted to be capable of
penetrating a 30 um thick mucus layer over time. Data represent three
independent experiments with > 120 nanoparticles tracked for each
experiment. Error bars are presented as s.e.m.
Figures 4a-c are schematics illustrating the influence of surface PEG
coverage ([F/F] ) on mucus penetration of nanoparticles. Figures 4a-c
shows the preparation of PLGA-PEG nanoparticles with surface PEG coating
at increasing coverage. As surface PEG coverage increases, PEG regime
changes from mushroom (neighboring PEG chains do not overlap, [F/I-1 <1,
Figure 4a), to brush (neighboring PEG chains overlap, 1<[17F*1<3, Figure
4b), to dense brush ([17F*]>3, Figure 4c). At low PEG coverage ([ripl <1,
Figure 4a), mucin fibers strongly adhere to nanoparticle core. At middle PEG
coverage (1<[F/Fl<3, Figure 4b), mucin fibers still can partially absorb to
the nanoparticle core. At high (prl>3, Figure 4c) PEG coverage, the
nanoparticle cores were completely shielded by the bioinert PEG corona
resulting in no adsorption of mucin to nanoparticles. Figure 4c shows that
nanoparticles with low PEG coverage are immobilized in mucus,
nanoparticles with middle PEG coverage are hindered or even immobilized
in mucus, and nanoparticles with high and very high PEG coverage are able
to rapidly penetrate mucus.
Figures 5A and 5B show vaginal coverage by Doxorubicin (Dox)
administered in either hypotonic (hypo) or isotonic (iso) solution. Mice (A)
remained supine for 1 hr prior to tissue collection (non-ambulatory) or (B)
6
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
were ambulatory for 10 minutes prior to tissue collection (ambulatory).
Images representative of the average vaginal surface coverage for
ambulatory mice dosed with Dox in (C) isotonic (iso) and (D) hypotonic
(hypo) solution. Data are means d SEM (n = 5). *P <0.05 compared to
isotonic, Wilcoxon rank-sum test.
Figure 6 shows the vaginal retention of Doxorubicin administered in
either isotonic (iso) or hypotonic (hypo) solution. Mice remained supine for
minutes prior to tissue collection. Overlay of Doxorubicin fluorescence
intensity and bright-field images for isotonic solution and hypotonic solution
10 in whole cervicovaginal tract tissue. The relative Doxorubicin signal
based
on quantification of fluorescent signal, adjusted for solution fluorescence
are
representative of the averages calculated for n = 4 mice and were quantified
as relative signal SEM. *P <0.05 compared to isotonic, Wilxocon rank-
sum test.
Figure 7 shows vaginal HSV-2 infection after treatment with
acyclovir monophosphate (ACVp) in either hypotonic (hypo) or isotonic
(iso) solution. ACVp (10 mg/ml) was administered 1 min or 60 min prior to
viral inoculum. n > 45 mice were tested in each group, and infection rates in
the control group were ¨90%. *P <0.05 compared to isotonic, Fisher's exact
test.
Figures 8A and 813 show vaginal retention of MPP administered in
either hypotonic (hypo) or isotonic (iso) solution. Figure 8A, mice remained
supine for 1 hr prior to tissue collection (non-ambulatory). Figure 813, mice
were ambulatory for 10 minutes prior to tissue collection (ambulatory).
Particle retention was calculated as mean SEM (n > 5). *P < 0.05 as
compared to isotonic, Wilcoxon rank-sum test.
Figure 9 shows vaginal distribution of fluorescent 100 nm MPPs
administered in solutions of varying osmolality in transverse vaginal
cryosections and on whole, flattened vaginal tissue. All tissues were
collected within 10 min of particle administration. All values have units
mOsm/kg. Osmolality for mucoadhesive CP particles was 20 mOsm/kg.
Images are representative of n > 5 mice. Data calculated as means SEM (n
> 3). #Reprinted from (4). *P <0.05 as compared to hypotonic solutions (20-
7
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
220), Wilcoxon rank-sum test.
DETAILED DESCRIPTION OF THE INVENTION
Many mucosal surfaces, such as those of the mouth, stomach,
intestines, colon, and vagina, contain numerous deep epithelial folds to
accommodate expansion of the epithelium and absorption of fluids and
nutrients. For these reasons, a significant portion of the epithelial surface
is
contained in these hard to access folds. The ability to engineer particles
that
uniformly distribute on mucosal tissue surfaces holds many important
implications for therapeutics delivery, imaging, and diagnostic applications.
For example, particles that do not achieve uniform distribution and penetrate
into the deep recesses fail to completely treat or protect a mucosal surface
(Rajapaksa et al. J Biol Chem 285, 23739-23746 (2010).
In the field of vaginal drug delivery, achieving adequate distribution
to all target surfaces is an often-cited problem. The vaginal surface is
highly
folded to accommodate expansion during intercourse and childbirth,
resulting in collapsed folds, or "rugae." Poor distribution into the rugae,
even
after simulated intercourse, has been cited as a critical factor in the
failure of
microbicide products to protect against vaginal infection. Other microbicide
studies in mice have used large volumes of test product (up to 40 ul), to
promote more complete vaginal distribution. The mouse vagina can hold a
volume of ¨50 ul; such a comparatively large volume of test agent distends
and unfolds the vaginal epithelium. In contrast, the human vagina can retain
in the range of 50 ml, while typical vaginal products deliver only 2-5 ml. To
investigate vaginal distribution in mice in vivo, a small volume (5 Ill) that
would more appropriately mimic the volumes used in humans was used. A
method that delivers drugs into the deep folded surfaces, without distending
the vagina, could lead to more effective vaginal drug delivery.
The vaginal epithelium is permeable to small molecules, and capable
of absorbing various drugs. The superficial layer of the vaginal epithelium
contains densely packed dead and dying cells (the stratum comeum) that
protects the deeper living cell layers while allowing secretion and absorption
of fluid through the epithelium. The vagina has a native capacity for
osmotically-induced fluid absorption that can be used for drug delivery.
8
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
Doxorubicin administered in hypotonic solution coated more than 85% of the
vaginal surface of ambulatory mice, whereas only 25% of the vaginal tissue
surface was coated with Doxorubicin administered in isotonic solution. The
isotonic fluid does not penetrate into the rugae, leaving a striping pattern
when the vaginal tissue is flattened. It has been suggested that hypotonic
delivery could increase the contraceptive efficacy of the detergent
nonoxyno1-9 (N9) by improving mobility of N9 through mucus (Dunmire
EN & Katz DF Contraception 55, 209-217 (1997); Owen et al. J Control
Release 60, 23-34 (1999)). Enhanced penetration of hypotonic N9 solution
though mucus was shown in isolated mucus in vitro, the focus being to
achieve more rapid contact between the detergent and sperm in the mucus..
Delivery to the cervicovaginal tract and colon in particular can be
challenging not only because of distribution issues, but also because of
"leakage". Most vaginal and rectal formulations are highly hyperosmolar,
which causes fluid to be osmotically secreted from the mucosal epithelium.
This fluid secretion leads to dilution and leakage of the formulation, along
with toxicity associated with the hyperosmolarity (Rudolph et al. Mol Ther
12, 493-501 (2005); Bertschinger et al. Journal of Controlled Release 116,
96-104 (2006); Pihl et al Acta Physiol 193, 67-78 (2008); Noach J
Pharrnacol Exp Ther 270, 1373-1380 (1994)). Drug absorption using
hypotonic drug solutions is known but not the effects of absorption on
distribution and retention. See, for example, Eyles et al. J Pharm Pharmacol
47, 561-565 (1995); Rajapaksa et al. J Biol Chem 285, 23739-23746 (2010);
Rudolph et al. Mol Ther 12, 493-501 (2005); Bertschinger et al. Journal of
Controlled Release 116, 96-104 (2006); Pihl et al. Acta Physiol 193, 67-78
(2008); Noach et al. J Pharmacol Exp Ther 270, 1373-1380 (1994);
Letmernas H Pharmaceut Res 12, 1573-1582 (1995).
Tonicity of a formulation depends on the permeability properties of
the tissue (colon versus vaginal, for example) and there is a critical mildly
hypotonic range for increased uptake and uniformity of distribution without
toxicity. Mildly hypotonic formulations should cause fluid absorption,
which would decrease the "leakage" often reported as an adverse side effect
by patients in clinical trials. This leaking of product leads to both
decreased
9
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
user acceptability, as well as rapid removal of the therapeutic agent. For
example, a reduction in osmolality from 294 mOsm/kg to 220 mOsm/kg
acted as a mildly hypotonic fluid that increased vaginal surface coverage
from 60% to 76%, and essentially all hypotonically delivered MPP were
drawn from the lumen to reach the epithelial surface deep within folded
surfaces within 10 min of administration.
Particulate formulations that rapidly achieve uniform distribution, as
well as transport through mucus, can be used to efficiently target mucus-
covered epithelia in the body for a wide spectrum of applications, including
drug therapies (ranging from small molecule therapeutics like
chemotherapeutics, to peptides, proteins, oligonucletoides, DNA, etc.),
imaging, and diagnostics. For therapeutic purposes, molecules entrapped in
the particles can then be released over prolonged times at predetermined
rates. In general, therapeutic applications for the technology include the
delivery of any drug where a standard formulation is not feasible, is not
100% effective, or leads to unwanted side-effects due to inefficient
distribution, toxicity, or "leakage". The method should also improve
penetration and uniform distribution of standard drug formulations (i.e.,
without drug delivery particles), specifically for gene/oligonucleotide
delivery; targeted and highly localized chemotherapy delivery to treat cancer;
targeted delivery of anti-inflammation drugs; treatment or prevention of
STDs; penetration into biofilms and other biological coatings/barriers; and
targeted delivery of antibiotics to treat bacterial infections.
Most vaginal gels have been formulated with excipients such as
glycerin or propylene glycol that render the gels hypertonic. Unfortunately,
recent investigations show that these hypertonic formulations cause toxicity
in the vaginal tract of mice that increases susceptibility to HSV-2 infection
(Moench et al. BMC Infect Dis 10, 331 (2010)), which is likely by being
hypertonic (Fuchs et al. J Infect Dis 195, 703-710 (2007); Clark MR &
Friend DR (2012) Pharmacokinetics and Topical Vaginal Effects of Two
Tenothvir Gels in Rabbits. AIDS Res Hum Retroviruses.). In addition a
hypertonic gel formulation was found to disrupt epithelial integrity in the
human colon, and a hypertonic tenofovir gel formulation was found to
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
induce epithelial fracture in ectocervical and colorectal explants compared
with tissues exposed to medium only (Rohan PLoS One 5, e9310 (2010)). It
has been postulated that a major contributing factor in the dextran sodium
sulfate (DSS)-induced experimental irritable bowel disease mouse model is
the hypertonicity of the DSS solution. Inflammatory cytokine release in
mouse vaginal lavage fluid was increased after 7 once-daily doses of a
hypertonic gel vehicle, but no increase after 7 once-daily doses of a
hypotonic formulation.
I. Definitions
"Nanoparticle," as used herein, generally refers to a particle of any
shape having a diameter from about 1 nm up to, but not including, about 1
micron, more preferably from about 5 urn to about 500 nm, most preferably
from about 5 mn to about 100 DM. Nanoparticles having a spherical shape
are generally referred to as "nanospheres".
"Mean particle size," as used herein, generally refers to the statistical
mean particle size (diameter) of the particles in a population of particles.
The diameter of an essentially spherical particle may be referred to as the
physical or hydrodynamic diameter. The diameter of a non-spherical particle
may refer preferentially to the hydrodynamic diameter. As used herein, the
diameter of a non-spherical particle may refer to the largest linear distance
between two points on the surface of the particle. Mean particle size can be
measured using methods known in the art, such as dynamic light scattering.
"Monodisperse" and "homogeneous size distribution," are used
interchangeably herein and describe a plurality of nanoparticles or
microparticles where the particles have the same or nearly the same diameter
or aerodynamic diameter. As used herein, a monodisperse distribution refers
to particle distributions in which 80, 81, 82, 83, 84, 85, 86, 86, 88, 89, 90,
91,
92, 93, 94, 95% or greater of the distribution lies within 5% of the mass
median diameter or aerodynamic diameter.
"Hydrophilic" as used herein refers to substances that have strongly
polar groups that readily interact with water.
"Lipophilic" refers to compounds having an affinity for lipids.
11
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
"Amphiphilic" refers to a molecule combining hydrophilic and
lipophilic (hydrophobic) properties
"Hydrophobic" as used herein refers to substances that lack an
affinity for water; tending to repel and not absorb water as well as not
dissolve in or mix with water.
"Pharmaceutically acceptable," as used herein, refers to compounds,
materials, compositions, and/or dosage forms which are, within the scope of
sound medical judgment, suitable for use in contact with the tissues of
human beings and animals without excessive toxicity, irritation, allergic
response, or other problems or complications commensurate with a
reasonable benefit/risk ratio, in accordance with the guidelines of agencies
such as the Food and Drug Administration.
"Biocompatible" and "biologically compatible," as used herein,
generally refer to materials that are, along with any metabolites or
degradation products thereof, generally non-toxic to the recipient, and do not
cause any significant adverse effects to the recipient. Generally speaking,
biocompatible materials are materials which do not elicit a significant
inflammatory or immune response when administered to a patient.
"Molecular weight," as used herein, generally refers to the relative
average chain length of the bulk polymer, unless otherwise specified. In
practice, molecular weight can be estimated or characterized using various
methods including gel permeation chromatography (GPC) or capillary
viscometry. GPC molecular weights are reported as the weight-average
molecular weight (Mw) as opposed to the number-average molecular weight
(Mn). Capillary viscometry provides estimates of molecular weight as the
inherent viscosity determined from a dilute polymer solution using a
particular set of concentration, temperature, and solvent conditions.
"Hydrophilic," as used herein, refers to the property of having affinity
for water. For example, hydrophilic polymers (or hydrophilic polymer
segments) are polymers (or polymer segments) which are primarily soluble
in aqueous solutions and/or have a tendency to absorb water. In general, the
more hydrophilic a polymer is, the more that polymer tends to dissolve in,
mix with, or be wetted by water.
12
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
"Hydrophobic," as used herein, refers to the property of lacking
affinity for, or even repelling water. For example, the more hydrophobic a
polymer (or polymer segment), the more that polymer (or polymer segment)
tends to not dissolve in, not mix with, or not be wetted by water.
"Mucus," as used herein, refers to a viscoelastic natural substance
containing primarily mucin glycoproteins and other materials, which protects
epithelial surface of various organs/tissues, including respiratory, nasal,
cervicovaginal, gastrointestinal, rectal, visual and auditory systems.
"Sputum," as used herein, refers to highly viscoelastic mucus secretions
consist of a variety of macromolecules such as DNA, actins and other cell
debris released from dead cells in addition to mucin glycoproteins. "Sputum"
is generally present in the pathogenic airways of patients afflicted by
obstructive lung diseases, including but not limited to, asthma, COPD and
CF. "CF mucus" and "CF sputum," as used herein, refer to mucus and
sputum, respectively, from a patient suffering from cystic fibrosis.
"Mucus Degrading Agent," as used herein, refers to a substance
which increases the rate of mucus clearance when administered to a patient.
Mucus degrading agents are known in the art. See, for example, Hanes, J. et
al, Gene Delivery to the Lung. in Pharmaceutical Inhalation Aerosol
Technology, Marcel Dekker, Inc., New York: 489-539 (2003). Examples of
mucus degrading agents include N-acetylcysteine (NAC), which cleaves
disulfide and sulfhydryl bonds present in mucin. Other mucus degrading
agents include mugwort, bromelain, papain, clerodendrum, acetylcysteine,
bromhexine, carbocisteine, eprazinone, mesna, ambroxol, sobrerol,
domiodol, denufosol, letosteine, stepronin, tiopronin, gelsolin, thymosin 134,
neltenexine, erdosteine, and various DNases including rhDNase.
The term "surfactant" as used herein refers to an agent that lowers the
surface tension of a liquid.
The term "therapeutic agent" refers to an agent that can be
administered to prevent or treat a disease or disorder. Therapeutic agents can
be a nucleic acid, a nucleic acid analog, a small molecule, a peptidomimetic,
a protein, peptide, carbohydrate or sugar, lipid, or surfactant, or a
combination thereof.
13
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
The term "treating" or preventing a disease, disorder or condition
from occurring in an animal which may be predisposed to the disease,
disorder and/or condition but has not yet been diagnosed as having it;
inhibiting the disease, disorder or condition, e.g., impeding its progress;
and
relieving the disease, disorder, or condition, e.g., causing regression of the
disease, disorder and/or condition. Treating the disease or condition includes
ameliorating at least one symptom of the particular disease or condition,
even if the underlying pathophysiology is not affected, such as treating the
pain of a subject by administration of an analgesic agent even though such
agent does not treat the cause of the pain.
The term "targeting moiety" as used herein refers to a moiety that
localizes to or away from a specific locale. The moiety may be, for example,
a protein, nucleic acid, nucleic acid analog, carbohydrate, or small molecule.
The entity may be, for example, a therapeutic compound such as a small
molecule, or a diagnostic entity such as a detectable label. The locale may be
a tissue, a particular cell type, or a subcellular compartment. In one
embodiment, the targeting moiety directs the localization of an active entity.
The active entity may be a small molecule, protein, polymer, or metal. The
active entity may be useful for therapeutic, prophylactic, or diagnostic
purposes.
The term "therapeutically effective amount" refers to an amount of
the therapeutic agent that, when incorporated into and/or onto particles
described herein, produces some desired effect at a reasonable benefit/risk
ratio applicable to any medical treatment. The effective amount may vary
depending on such factors as the disease or condition being treated, the
particular targeted constructs being administered, the size of the subject, or
the severity of the disease or condition. One of ordinary skill in the art may
empirically deteiniine the effective amount of a particular compound without
necessitating undue experimentation.
The terms "incorporated" and "encapsulated" refers to incorporating,
formulating, or otherwise including an active agent into and/or onto a
composition that allows for release, such as sustained release, of such agent
in the desired application. The terms contemplate any manner by which a
14
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
therapeutic agent or other material is incorporated into a polymer matrix,
including, for example: attached to a monomer of such polymer (by covalent,
ionic, or other binding interaction), physical admixture, enveloping the agent
in a coating layer of polymer, incorporated into the polymer, distributed
throughout the polymeric matrix, appended to the surface of the polymeric
matrix (by covalent or other binding interactions), encapsulated inside the
polymeric matrix, etc. The term "co-incorporation" or "co-encapsulation"
refers to-the incorporation of a therapeutic agent or other material and at
least one other therapeutic agent or other material in a subject composition.
Conventional use of the term "isotonic" refers to fluids that do not
cause cells to swell or shrink, which typically occurs when the total solute
concentrations (osmolality) is equal to that of the blood (-300 mOsrn/kg).
Isotonic is defined herein as a formulation that does not cause water to enter
or leave the lumen or be driven osmotically through the epitheliuim.
Hypotonic is defined herein to refer to formulations that cause water to flow
inward, toward the epithelium from the mucosal surface, and hypertonic
formulations are defined as those that cause water to flow outward, toward
the mucus-coated surface.
"Mucus-penetrating particle" or "MPP", as used herein, generally
refers to particles which have been coated with a mucosal penentration
enhancing coating. In some embodiments, the particles are particles of an
active agent, such as a therapeutic, diagnostic, prophylactic, and/or
nutraceutical agent (i.e., drug particle) that is coated with a mucosal
penetrating enhancing coating as described below. In other embodiments,
the particles are formed of a matrix material, such as a polymeric material,
in
which the therapeutic, diagnostic, prophylactic, and/or nutraceutical agent is
encapsulated, dispersed, and/or associated. The coating material can be
covalently or non-covalently associated with the drug particle or polymeric
particle
15
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
IL Mucus-penetrating nanoparticles (MPPs)
A. Polymeric particles
I. Core Polymer
Any number of biocompatible polymers can be used to prepare the
nanoparticles. In one embodiment, the biocompatible polymer(s) is
biodegradable. In another embodiment, the particles are non-degradable. In
other embodiments, the particles are a mixture of degradable and non-
degradable particles.
Exemplary polymers include, but are not limited to, cyclodextrin-
containing polymers, in particular cationic cyclodextrin-containing polymers,
such as those described in U.S. Patent No. 6,509,323; polymers prepared
from lactones, such as poly(caprolactone) (PCL); polyhydroxy acids and
copolymers thereof such as poly(lactic acid) (PLA), poly(L-lactic acid)
(PLLA), poly(glycolic acid) (PGA), poly(lactic acid-co-glycolic acid)
(PLGA), poly(L-lactic acid-co-glycolic acid) (PLLGA), poly(D,L-lactide)
(PDLA), poly(D,L-lactide-co-caprolactone), poly(D,L-lactide-co-
caprolactone-co-glycolide), poly(D,L-lactide-co-PEO-co-D,L-lactide),
poly(D,L-lactide-co-PPO-co-D,L-lactide), and blends thereof, polyalkyl
cyanoacralate, polyurethanes, polyamino acids such as poly-L-lysine (PLL),
poly(valeric acid), and poly-L-glutamic acid; hydroxypropyl methacrylate
(HPMA); polyanhydrides; polyesters; polyorthoesters; poly(ester amides);
polyamides; poly(ester ethers); polycarbonates; polyalkylenes such as
polyethylene and polypropylene; polyalkylene glycols such as poly(ethylene
glycol) (PEG) and polyalkylene oxides (PEO), and block copolymers thereof
such as polyoxyalkylene oxide ("PLURONICSO"); polyalkylene
terephthalates such as poly(ethylene terephthalate); ethylene vinyl acetate
polymer (EVA); polyvinyl alcohols (PVA); polyvinyl ethers; polyvinyl
esters such as poly(vinyl acetate); polyvinyl halides such as poly(vinyl
chloride) (PVC), polyvinylpyrrolidone; polysiloxarxes; polystyrene (PS;
celluloses including derivatized celluloses such as alkyl celluloses,
hydroxyalkyl celluloses, cellulose ethers, cellulose esters, nitro celluloses,
hydroxypropylcellulose, and carboxymethylcellulose; polymers of acrylic
acids, such as poly(methyl(meth)acrylate) (PMMA),
16
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
poly(ethyl(meth)acrylate), poly(butyl(meth)acrylate),
poly(isobutyl(meth)acrylate), poly(hexyl(meth)acrylate),
poly(isodecyl(meth)acrylate), poly(lauryl(rneth)acrylate),
poly(phenyl(meth)acrylate), poly(methyl acrylate), poly(isopropyl acrylate),
poly(isobutyl acrylate), poly(octadecyl acrylate) (jointly referred to herein
as
"polyacrylic acids"); polydioxanone and its copolymers;
polyhydroxyalkanoates; polypropylene ftunarate; polyoxymethylene;
poloxamers; poly(butyric acid); trimethylene carbonate; and
polyphosphazenes,. Examples of preferred natural polymers include proteins
such as albumin, collagen, gelatin and prolamines,. for example, zein, and
polysaccharides such as alginate. Copolymers of the above, such as random,
block, or graft copolymers, or blends of the polymers listed above can also
be used.
Functional groups on the polymer can be capped to alter the
properties of the polymer and/or modify (e.g., decrease or increase) the
reactivity of the functional group. For example, the carboxyl termini of
carboxylic acid contain polymers, such as lactide- and glycolide-containing
polymers, may optionally be capped, e.g., by esterification, and the hydroxyl
termini may optionally be capped, e.g. by etherification or esterification.
Copolymers of PEG or derivatives thereof with any of the polymers
described above may be used to make the polymeric particles. In certain
embodiments, the PEG or derivatives may be located in the interior positions
of the copolymer. Alternatively, the PEG or derivatives may locate near or at
the terminal positions of the copolymer. For example, one or more of the
polymers above can be terminated with a block of polyethylene glycol. In
some embodiments, the core polymer is a blend of pegylated polymer and
non-pegylated polymer, wherein the base polymer is the same (e.g., PLGA
and PLGA-PEG) or different (e.g., PLGA-PEG and PLA). In certain
embodiments, the microparticles or nanoparticles are formed under
conditions that allow regions of PEG to phase separate or otherwise locate to
the surface of the particles. The surface-localized PEG regions alone may
perform the function of, or include, the surface-altering agent. In particular
embodiments, the particles are prepared from one or more polymers
17
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
terminated with blocks of polyethylene glycol as the surface-altering
material.
The weight average molecular weight can vary for a given polymer
but is generally from about 1000 Daltons to 1,000,000 Daltons, 1000 Daltons
to 500,000 Dalton, 1000 Daltons to 250,000 Daltons, 1000 Daltons to
100,000 Daltons, 5,000 Daltons to 100,000 Daltons, 5,000 Daltons to 75,000
Daltons, 5,000 Daltons to 50,000 Daltons, or 5,000 Daltons to 25,000
Daltons.
In some embodiments, the particles may be used as nanoparticle gene
carriers. In these embodiments, the particles can be formed of one or more
polycationic polymers which complex with one or more nucleic acids which
are negatively charged. The cationic polymer can be any synthetic or natural
polymer bearing at least two positive charges per molecule and having
sufficient charge density and molecular size to bind to nucleic acid under
physiological conditions (L e., pH and salt conditions encountered within the
body or within cells). In certain embodiments, the polycationic polymer
contains one or more amine residues.
B. Coated drug particles
In some embodiments, the particles of the therapeutic, diagnostic,
prophylactic, and/or nutriceutical agent is coated with mucosal penetration
enhancing coating. The particle can be microparticles or nanoparticles.
Exemplary therapeutic, diagnostic, prophylactic, and/or nutriceutical agents
are described in more detail below. The drug particles can be coated with
mucosal penetration enhancing coating materials using techniques known in
the art. The density and morphology of the coating can be evaluated as
described below. The mucosal penetration enhancing coating can be
covalently or non-covalently associated with the agent. In some
embodiments, it is non-covalently associated. In other embodiments, the
active agent contains a reactive functional group or one is incorporated to
which the mucosal penetration enhancing coating can be covalently bound.
C. Materials that promote diffusion through mucus
The micro- and/or nanoparticles preferably are coated with or contain
one or more surface altering agents or materials. "Surface-alternating
18
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
agents", as used herein refers to an agent or material which modifies one or
more properties of the particles for the surface, including, but not limited
to,
hydrophilicity (e.g., makes the particles more or less hydrophilic), surface
charge (e.g., makes the surface neutral or near neutral or more negative or
positive), and/or enhances transport in or through bodily fluids and/or
tissues, such as mucus. In some embodiments, the surface-alternating
material provides a direct therapeutic effect, such as reducing inflammation.
Examples of the surface-altering agents include, but are not limited
to, proteins, including anionic proteins (e.g., albumin), surfactants, sugars
or
sugar derivatives (e.g., cyclodextrin), therapeutics agents, and polymers.
Preferred polymers include heparin, polyethylene glycol ("PEG") and
poloxomers (polyethylene oxide block copolymers). The most preferred
material is PEG or PLURONIC F1270, a polyethylene oxide block
copolymer available from BASF.
Examples of surfactants include, but are not limited to, L-a-
phosphatidylcholine (PC), 1 ,2-dipalmitoylphosphatidycholine (DPPC), oleic
acid, sorbitan trioleate, sorbitan mono-oleate, sorbitan monolaurate,
polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan
monooleate, natural lecithin, oleyl polyoxyethylene (2) ether, stearyl
polyoxyethylene (2) ether, lauryl polyoxyethylene (4) ether, block
copolymers of oxyethylene and oxypropylene, synthetic lecithin, diethylene
glycol dioleate, tetrahydrofurfuryl oleate, ethyl oleate, isopropyl myristate,
glyceryl monooleate, glyceryl monostearate, glyceryl monoricinoleate, cetyl
alcohol, stearyl alcohol, polyethylene glycol 400, cetyl pyridinium chloride,
benzalkonium chloride, olive oil, glyceryl monolaurate, corn oil, cotton seed
oil, and sunflower seed oil, lecithin, oleic acid, and sorbitan trioleate.
In one embodiment, the particles are coated with or contain
polyethylene glycol (PEG) or F127. Alternatively, the PEG or F127can be in
the form of blocks covalently bound (e.g., in the interior or at one or both
terminals) to the core polymer used to form the particles. In particular
embodiments, the particles are formed from block copolymers containing
PEG. In more particular embodiments, the particles are prepared from block
copolymers containing PEG, wherein PEG is covalently bound to the
19
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
terminal of the base polymer. Representative PEG molecular weights include
300 Da, 600 Da, 1 kDa, 2 kDa, 3 kDa, 4 kDa, 6 kDa, 8 kDa, 10 kDa, 15 kDa,
20 kDa, 30 kDa, 50 kDa, 100 kDa, 200 kDa, 500 kDa, and 1 MDa and all
values within the range of 300 Daltons to 1 MDa. In preferred embodiments,
the PEG has a molecular weight of about 5kD. PEG of any given molecular
weight may vary in other characteristics such as length, density, and
branching.
1. Evaluating surface density
Surface density of poly(ethylene glycol) (PEG) on microparticles
and/or nanoparticles is a key parameter in determining their successful
applications in-vivo. (As used herein, general references to PEG on the
surface of particles is extrapolatable to PLURONIC F127. The controlled
delivery of drugs to mucosal surfaces is challenging because of the presence
of the protective mucus layer, and the mucus-penetrating particles show
promise at improved drug distribution, retention and efficacy at mucosal
surfaces. The dense coating of PEG on biodegradable nanoparticles can
allow rapid penetration through mucus because of the greatly reduced
adhesive interaction between mucus constituents and nanoparticles.
In a preferred embodiment, nuclear magnetic resonance (NMR) is
used to assess the surface PEG density on PEG-containing polymeric
nanoparticles described herein, both qualitatively and quantitatively (PEG
peak typically observed ¨3.65 ppm). When nanoparticles are dispersed
within the NMR solvent D20, only the surface PEG, not the PEG embedded
within the core, can be directly detected by NMR. Therefore, NMR provides
a means for directly measure the surface density of PEG.
In some embodiments, PEG surface density can be controlled by
preparing the particles from a mixture of pegylated and non-pegylated
particles. For example, the surface density of PEG on PLGA nanoparticles
can be precisely controlled by preparing particles from a mixture of
poly(lactic-co-glycolic acid) and poly(ethylene glycol) (PLGA-PEG).
Quantitative 111 nuclear magnetic resonance (NMR) can be used to measure
the surface PEG density on nanoparticles. Multiple particle tracking in
human mucus and the study of mucin binding and tissue distribution in
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
mouse vagina revealed that there exists a PEG density threshold, which is
approximately, 10-16 PEG chains/100nm2, for PLGA-PEG nanoparticles to
be effective in penetrating mucus. This density threshold may vary
depending on a variety of factors including the core polymer used to prepare
the particles, particle size, and/or molecular weight of PEG.
The density of the coating can be varied based on a variety of factors
including the surface altering material and the composition of the particle.
In
one embodiment, the density of the surface altering material, such as PEG, as
measured by H NMR is at least, 0.1, 0.2, 0.5, 0.8, 1, 2, 5, 8, 10, 15, 20, 25,
40, 50, 60, 75, 80, 90, or 100 chains per nm2. The range above is inclusive
of all values from 0.1 to 100 units per nm2. In particular embodiments, the
density of the surface altering material, such as PEG, is from about 1 to
about 25 chains/nm2, from about 1 to about 20 chains/nm2, from about 5 to
about 20 chains/nm2, from about 5 to about 18 chains/nm2, from about 5 to
about 15 chains/nm2, or from about 10 to about 15 chains/nm2. In other
particular embodiments, the density is from about 0.05 to about 0.5 PEG
chains/nm2.
The concentration of the surface altering material, such as PEG, can
also be varied. In particular embodiments, the density of the surface-altering
material (e.g., PEG) is such that the surface-altering material (e.g. PEG)
adopted an extended brush configuration. In other embodiments, the mass
of the surface-altering moiety is at least 1/10,000, 1/7500, 1/5000, 1/4000,
1/3400, 1/2500, 1/2000, 1/1500, 1/1000, 1/750, 1/500, 1/250, 1/200, 1/150,
1/100, 1/75, 1/50, 1/25, 1/20, 1/5, 1/2, or 9/10 of the mass of the particle.
The range above is inclusive of all vales from 1/10,000 to 9/10.
D. Emulsifier
The particles described herein can contain an emulsifier, particularly
a low molecular weight emulsifier. The emulsifier is incorporated into the
particle during particle formation and therefore is a component of the
finished particle. The emulsifier can be encapsulated within the particle, be
dispersed in whole or in part within the polymer matrix (e.g., part of the
emulsifier extends out from the polymer matrix), and/or is associated (e.g.,
covalently or non-covalently) with the surface of the particle.
21
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
"Low molecular weight", as used herein, generally refers to an
emulsifier having a molecular weight less than 1500, 1400, 1300, 1200,
1100, 1000, 900, 800, 700, 600, 500, 400, or 300 amu. In some
embodiments, the molecular weight is less than 1300 amu. In some
embodiments, the molecular weight is from about 300 amu to about 1200
amu.
The emulsifier can be positively charged, negatively charged, or
neutral. Examples of negatively charged emulsifiers include, but are not
limited to, cholic acid sodium salt (CHA, MW = 430) and dioctyl
sulfosuccinate sodium (DSS, MW = 455). Examples of positively charged
emulsifiers include, but are not limited to, hexadecyltrimethyl ammonium
bromide (CTAB, MW = 364). Examples of neutral emulsifiers include, but
are not limited to, sapon (MW = 1191), TWEEN 20 (MW = 1,225), TWEEN
80 (MW = 1310), and sugar ester D1216 (sucrose laurate, SE, MW = 524).
In addition to having a low molecular weight, the emulsifier must be capable
of suitably stabilizing the emulsion droplets during particle formation in
order to prevent particle aggregation. In addition to suitably stabilizing the
emulsion droplets to prevent aggregate formation, the stabilizer must be
small enough to be completely shielded at the particle surface by the surface
altering material corona (e.g., PEG) to provide a neutral or near neutral
surface charge. The transport of charged particles may be hindered due to
the interaction of the charged particles with oppositely charged species in
vivo. For example, the ability of the particles to penetrate mucus rapidly is
dependent, at least in part, on the surface charge of the particles. In order
to
facilitate their diffusion through mucus, the nanoparticles described herein
typically possess a near neutral surface charge. In certain embodiments, the
nanoparticle possess a (-potential of between about 10 mV and about -10
mV, preferably between about 5 mV and about -5 mV, preferably between
about 3 mV and about -3 mV, more preferably between about 2 mV and
about -2 mV.
While the particles described herein are referred to as nanoparticles,
and thus typically have an average diameter in the range of 1 nrn up to, but
not including, about 1 micron, more preferably from about 5 nm to about 500
22
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
nm, most preferably from about 5 urn to about 100 nm. In certain
embodiments, the average diameter of the particles is form about 100 nm to
about 150 nm. However, particles can be prepared that are sized in the
micron-range. The conditions and/or materials used to prepare the particles
can be varied to vary the size of the particles.
In certain embodiments, the nanoparticles retain their particle size and
-potential after nebulization or storage for at least 1 month, more preferably
at least 2 months, most preferably at least 3 months at 4 C.
2. Effect of emulsifier on transport ability
In some embodiments, the particles are administered to penetrate to
the mucus for drug delivery to the mucosa. The particles described herein
contain a surface-altering material which can enhance transport through the
mucus. For example, PEG-containing block copolymers can self-assemble
to form dense, muco-inert PEG coatings on the surface of emulsion droplets
formed by the emulsification method.
Therapeutic, prophylactic, nutraceutical and/or diagnostic
agent
I. Therapeutic agents
In some embodiments, the particles have encapsulated therein,
dispersed therein, and/or covalently or non-covalently associate with the
surface one or more therapeutic agents. The therapeutic agent can be a small
molecule, protein, polysaccharide or saccharide, nucleic acid molecule
and/or lipid.
i. Small molecule therapeutic agents
Exemplary classes of small molecule therapeutic agents include, but
are not limited to, analgesics, anti-inflammatory drugs, antipyretics,
antidepressants, antiepileptics, antiopsychotic agents, neuroprotective
agents,
anti-proliferatives, such as anti-cancer agent, anti-infectious agents, such
as
antibacterial agents and antifungal agents, antihistamines, antimigraine
drugs, antimuscarinics, anxioltyics, sedatives, hypnotics, antipsychotics,
bronchodilators, anti-asthma drugs, cardiovascular drugs, corticosteroids,
dopaminergics, electrolytes, gastro-intestinal drugs, muscle relaxants,
nutritional agents, vitamins, parasympathomimetics, stimulants, anorectics
23
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
and anti-narcoleptics. Nutraceuticals can also be incorporated. These may be
vitamins, supplements such as calcium or biotin, or natural ingredients such
as plant extracts or phytohormones.
i. Nucleic acids
In some embodiments, the agent is one or more nucleic acids. The
nucleic acid can alter, correct, or replace an endogenous nucleic acid
sequence The nucleic acid is used to treat cancers, correct defects in genes
in
other pulmonary diseases and metabolic diseases affecting lung function,
genes such as those for the treatment of Parkinsons and ALS where the genes
reach the brain through nasal delivery.
Gene therapy is a technique for correcting defective genes
responsible for disease development. Researchers may use one of several
approaches for correcting faulty genes: A normal gene may be inserted into
a nonspecific location within the genome to replace a nonfunctional gene.
An abnormal gene can be swapped for a normal gene through homologous
recombination. The abnormal gene can be repaired through selective reverse
mutation, which returns the gene to its normal function. The regulation (the
degree to which a gene is turned on or off) of a particular gene can be
altered.
The nucleic acid can be a DNA, RNA, a chemically modified nucleic
acid, or combinations thereof. For example, methods for increasing stability
of nucleic acid half-life and resistance to enzymatic cleavage are known in
the art, and can include one or more modifications or substitutions to the
nucleobases, sugars, or linkages of the polynucleotide. The nucleic acid can
be custom synthesized to contain properties that are tailored to fit a desired
use. Common modifications include, but are not limited to use of locked
nucleic acids (LNAs), unlocked nucleic acids (UNAs), morpholinos, peptide
nucleic acids (PNA), phosphorothioate linkages, phosphonoacetate linkages,
propyne analogs, TAD-methyl RNA, 5-Me-dC, 21-5' linked phosphodiester
linage, Chimeric Linkages (Mixed phosphorothioate and phosphodiester
linkages and modifications), conjugation with lipid and peptides, and
combinations thereof.
24
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
In some embodiments, the nucleic acid includes internucleotide
linkage modifications such as phosphate analogs having achiral and
uncharged intersubunit linkages (e.g., Sterchak, E. P. et al., Organic Chem.,
52:4202, (1987)), or uncharged morpholino-based polymers having achiral
intersubunit linkages (see, e.g., U.S. Patent No. 5,034,506). Some
intemucleotide linkage analogs include morpholidate, acetal, and polyamide-
linked heterocycles. Other backbone and linkage modifications include, but
are not limited to, phosphorothioates, peptide nucleic acids, tricyclo-DNA,
decoy oligonucleotide, ribozyrnes, spiegelmers (containing L nucleic acids,
an apatamer with high binding affinity), or CpG oligomers.
Phosphorothioates (or S-oligos) are a variant of normal DNA in
which one of the nonbridging oxygens is replaced by a sulfur. The
sulfurization of the intemucleotide bond dramatically reduces the action of
endo-and exonucleases including 5' to 3' and 3' to 5' DNA POL I
exonuclease, nucleases S 1 and Pi RNases, serum nucleases and snake
venom phosphodiesterase. in addition, the potential for crossing the lipid
bilayer increases. Because of these important improvements,
phosphorothioates have found increasing application in cell regulation.
Phosphorothioates are made by two principal routes: by the action of a
solution of elemental sulfur in carbon disulfide on a hydrogen phosphonate,
or by the more recent method of sulfurizing phosphite triesters with either
tetraethylthiuram disulfide (TETD) or 3H-1, 2-bensodithio1-3-one 1, 1-
dioxide (BDTD). The latter methods avoid the problem of elemental sulfur's
insolubility in most organic solvents and the toxicity of carbon disulfide.
The
TETD and BDTD methods also yield higher purity phosphorothioates.
Peptide nucleic acids (PNA) are molecules in which the phosphate
backbone of oligonucleotides is replaced in its entirety by repeating N-(2-
aminoethyl)-glycine units and phosphodiester bonds are replaced by peptide
bonds. The various heterocyclic bases are linked to the backbone by
methylene carbonyl bonds. PNAs maintain spacing of heterocyclic bases
that is similar to oligonucleotides, but are achiral and neutrally charged
molecules. Peptide nucleic acids are typically comprised of peptide nucleic
acid monomers. The heterocyclic bases can be any of the standard bases
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
(uracil, thymine, cytosine, adenine and guanine) or any of the modified
heterocyclic bases described below. A PNA can also have one or more
peptide or amino acid variations and modifications. Thus, the backbone
constituents of PNAs may be peptide linkages, or alternatively, they may be
non-peptide linkages. Examples include acetyl caps, amino spacers such as
8-amino-3,6-dioxaoctanoic acid (referred to herein as 0-linkers), and the
like. Methods for the chemical assembly of PNAs are well known.
In some embodiments, the nucleic acid includes one or more
chemically-modified heterocyclic bases including, but are not limited to,
inosine, 5-(1-propynyl) uracil (pU), 5-(1-propynyl) cytosine (pC), 5-
methylcytosine, 8-oxo-adenine, pseudocytosine, pseudoisocytosine, 5 and 2-
amino-5-(2'-deoxy-P-D-ribofiiranosy1)pyridine (2-aminopyridine), and
various pyrrolo- and pyrazolopyrimidine derivatives, 4-acetylcytosine, 8-
hydroxy-N-6-methyladenosine, aziridinylcyto sine, 5-
(carboxyhydroxylmethyl) uracil, 5-bromouracil, 5-
carboxymethylaminomethy1-2-thiouracil, 5-
carboxymethylaminomethyluracil, dihydrouracil, N6-isoperitenyladenine, 1-
methyladenine, 1-methylpseudouracil, 1-methyl guanine, 1-methylinosine,
2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine ,
N6-methyladenine, 7-methylguanine, 5-methylaminomethyluracil, 5-
methoxy-aminomethy1-2-thiouracil, beta-D-mannosylqueosine, 5'-
methoxycarbonylmethyluracil, 5-methoxyuracil, 2-methylthio-N6-
isopentenyladenine, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic
acid, oxybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-
thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, N-uracil-5-oxyacetic
acid methylester, 2,6-diaminopurine, and 21-modified analogs such as, but
not limited to 0-methyl, amino-, and fluoro-modified analogs. Inhibitory
RNAs modified with 2'-flouro (2'-F) pyiimidines appear to have favorable
properties in vitro.
In some embodiments the nucleic acid includes one or more sugar
moiety modifications, including, but are not limited to, 2'-49-aminoethoxy,
2'-0-amonioethyl (2%0AE), 2'-0-methoxy, 2'-0-methyl, 2-guanidoethyl
26
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
(2'-OGE), 2'-49,4'-C-methylene (LNA), 2'-0-(methoxyethyl) (2'-OME) and
2'-0-(N-(methypacetamido) (2'-OMA).
Methods of gene therapy typically rely on the introduction into the
cell of a nucleic acid molecule that alters the genotype of the cell.
Introduction of the nucleic acid molecule can correct, replace, or otherwise
alters the endogenous gene via genetic recombination. Methods can include
introduction of an entire replacement copy of a defective gene, a
heterologous gene, or a small nucleic acid molecule such as an
oligonucleotide. This approach typically requires delivery systems to
introduce the replacement gene into the cell, such as genetically engineered
viral vectors.
Methods to construct expression vectors containing genetic sequences
and appropriate transcriptional and translational control elements are well
known in the art. These methods include in vitro recombinant DNA
techniques, synthetic techniques, and in vivo genetic recombination.
Expression vectors generally contain regulatory sequences necessary
elements for the translation and/or transcription of the inserted coding
sequence. For example, the coding sequence is preferably operably linked to
a promoter and/or enhancer to help control the expression of the desired gene
product. Promoters used in biotechnology are of different types according to
the intended type of control of gene expression. They can be generally
divided into constitutive promoters, tissue-specific or development-stage-
specific promoters, inducible promoters, and synthetic promoters.
Viral vectors include adenovirus, adeno-associated virus, herpes
virus, vaccinia virus, polio virus, AIDS virus, neuronal trophic virus,
Sindbis
and other RNA viruses, including these viruses with the HIV backbone.
Also useful are any viral families which share the properties of these viruses
which make them suitable for use as vectors. Typically, viral vectors
contain, nonstructural early genes, structural late genes, an RNA polymerase
III transcript, inverted terminal repeats necessary for replication and
encapsidation, and promoters to control the transcription and replication of
the viral genome. When engineered as vectors, viruses typically have one or
27
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
more of the early genes removed and a gene or gene/promoter cassette is
inserted into the viral genome in place of the removed viral DNA.
Gene targeting via target recombination, such as homologous
recombination (HR), is another strategy for gene correction. Gene correction
at a target locus can be mediated by donor DNA fragments homologous to
the target gene (Hu, et al., Mol. Biotech., 29:197-210 (2005); Olsen, et al.,
J.
Gene Med., 7:1534-1544 (2005)). One method of targeted recombination
includes the use of triplex-forming oligonucleotides (TF0s) which bind as
third strands to homopurine/homopyrimidine sites in duplex DNA in a
= 10 sequence-specific manner. Triplex forming oigonucleotides can interact
with
either double-stranded or single-stranded nucleic acids. When triplex
molecules interact with a target region, a structure called a triplex is
formed,
in which there are three strands of DNA fowling a complex dependent on
both Watson-Crick and Hoogsteen base-pairing. Triplex molecules are
= 15 preferred because they can bind target regions with high affinity and
specificity. It is preferred that the triplex forming molecules bind the
target
= molecule with a Kd less than 10-6, 10-8, 10-10, or 10-12. Methods for
targeted gene therapy using triplex-forming oligonucleotides (TFO's) and
peptide nucleic acids (PNAs) are described in U.S. Published Application
20 No. 20070219122 and their use for treating infectious diseases such
as HIV
are described in U.S. Published Application No. 2008050920. The triplex-
forming molecules can also be tail clamp peptide nucleic acids (tcPNAs),
such as those described in U.S. Published Application No.2011/0262406.
Double duplex-forming molecules, such as a pair of
25 pseudocomplementary oligonucleotides, can also induce recombination
with
a donor oligonucleotide at a chromosomal site. Use of
pseudocomplementary oligonucleotides in targeted gene therapy is described
in U.S. Published Application No. 2011/0262406.
2, Diagnostic Agents
30 Exemplary diagnostic materials include paramagnetic
molecules,
fluorescent compounds, magnetic molecules, and radionuclides. Suitable
diagnostic agents include, but are not limited to, x-ray imaging agents and
contrast media. Radionuclides also can be used as imaging agents.
28
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
Examples of other suitable contrast agents include gases or gas emitting
compounds, which are radioopaque. Nanoparticles can further include
agents useful for determining the location of administered particles. Agents
useful for this purpose include fluorescent tags, radionuclides and contrast
agents.
III. Pharmaceutical compositions
For those embodiments where the one or more therapeutic,
prophylactic, and/or diagnostic agents are encapsulated within a polymeric
nanoparticle and/or associated with the surface of the nanoparticle, the
percent drug loading is from about 1% to about 80%, from about 1% to
about 50%, preferably from about 1% to about 40% by weight, more
preferably from about 1% to about 20% by weight, most preferably from
about 1% to about 10% by weight. The ranges above are inclusive of all
values from 1% to 80%. For those embodiments where the agent is
associated with the surface of the particle, the percent loading may be higher
since the amount of drug is not limited by the methods of encapsulation. In
some embodiments, the agent to be delivered may be encapsulated within a
nanoparticle and associated with the surface of the particle.
The formulations described herein contain an effective amount of
nanoparticles ("MPPs") in a pharmaceutical carrier appropriate for
administration to a mucosa' surface, wherein the pharmaceutical carrier is
adjusted to be hypotonic. One skilled in the art can routinely adjust tonicity
of pharmaceutical carriers, once the desired tissue to be treated is
identified,
based on the preferred tonicity ranges described herein.
Tonicity is the 'effective osmolality` and is equal to the sum of the
concentrations of the solutes which have the capacity to exert an osmotic
force across the membrane. A number of different materials can be used to
adjust tonicity. For example, the USP 29-NF 24 lists five excipients
classified as "tonicity" agents, including dextrose, glycerin; potassium
chloride; mannitol; and sodium chloride See, for example, United States
Pharmacopeia' Convention, Inc. United States Pharmacopeia 29-National
Formulary 24. Rockville MD: U.S. Pharmacopeia' Convention, Inc.; 2005:
3261; Day, A. Dextrose. In: Rowe RC, Sheskey RI and Owen SC, eds.
29
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
Handbook of Pharmaceutical Excipients. 5th ed. Washington DC: American
Pharmaceutical Association; 2005: 231-233; Price JC. Glycerin. In: Rowe
RC, Sheskey PJ and Owen SC, eds. Handbook of Pharmaceutical Excipients.
5th ed. Washington DC: American Pharmaceutical Association; 2005: 301-
303; Price JC. Glycerin. In: Rowe RC, Sheskey PJ and Owen SC, eds.
Handbook of Pharmaceutical Excipients. 5th ed. Washington DC: American
Pharmaceutical Association; 2005: 301-303; Armstrong NA. Mannitol. In:
Rowe RC, Sheskey PJ and Owen SC, eds. Handbook of Pharmaceutical
Excipients. 5th ed. Washington DC: American Pharmaceutical Association;
2005: 449-453; Owen SC. Sodium Chloride. In: Rowe RC, Sheskey PJ and
Owen SC, eds. Handbook of Pharmaceutical Excipients. 5th ed. Washington
DC: American Pharmaceutical Association; 2005: 671-674. Mannitol is an
example of a GRAS listed ingredient accepted for use as a food additive in
Europe, included in the FDA Inactive Ingredients Database (IP, 1M, IV, and
SC injections; infusions; buccal, oral and sublingual tablets, powders and
capsules; ophthalmic preparations; topical solutions), included in
nonparenteral and parenteral medicines licensed in the UK and included in
the Canadian Natural Health Products Ingredients Database. A 5.07% w/v
aqueous solution is isoosmotic with serum.
Minimally hypotonic formulations, preferably ranging from 20-220
mOsm/kg, provide rapid and unifoHn delivery of MPP to the entire vaginal
surface, with minimal risk of epithelial toxicity. There is a higher
osmolality
in the colon, such that vehicles with an osmolality above that of blood
plasma (generally considered isotonic at ¨300 mOsm/kg), leads to
improvements in distribution in the colon. The range for improved colon
distribution with a hy-potonic vehicle in the colon is ¨20 mOsm/kg-450
mOsm/kg if a major fraction of the solutes in the formulation consists of Na+
ions, since these will be actively taken up (absorbed) by the epithelium, thus
making the formulation effectively hypotonie even though it is hyperosmolal
with respect to blood.
A. Pulmonary formulations
Pharmaceutical formulations and methods for the pulmonary
administration of active agents to patients are known in the art.
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
The respiratory tract is the structure involved in the exchange of gases
between the atmosphere and the blood stream. The respiratory tract
encompasses the upper airways, including the oropharynx and larynx,
followed by the lower airways, which include the trachea followed by
bifurcations into the bronchi and bronchioli. The upper and lower airways
are called the conducting airways. The terminal bronchioli then divide into
respiratory bronchioli which then lead to the ultimate respiratory zone, the
alveoli, or deep lung, where the exchange of gases occurs.
Formulations can be divided into dry powder formulations and liquid
formulations. Both dry powder and liquid formulations can be used to form
aerosol formulations. The term aerosol as used herein refers to any
preparation of a fine mist of particles, which can be in solution or a
suspension, whether or not it is produced using a propellant.
1. Dry Powder Formulations
Dry powder formulations are finely divided solid formulations
containing nanoparticle carriers which are suitable for pulmonary
administration. Dry powder formulations include, at a minimum, one or
more nanoparticle carriers which are suitable for pulmonary administration.
Such dry powder formulations can be administered via pulmonary inhalation
to a patient without the benefit of any carrier, other than air or a suitable
propellant.
In other embodiments, the dry powder formulations contain one or
more nanoparticle gene carriers in combination with a pharmaceutically
acceptable carrier. In these embodiments, the nanoparticle gene carriers and
pharmaceutical carrier can be formed into nano- or microparticles for
delivery to the lung.
The pharmaceutical carrier may include a bulking agent or a lipid or
surfactant. Natural surfactants such as dipalmitoylphosphatidylcholine
(DPPC) are the most preferred. Synthetic and animal derived pulmonary
surfactants include Exosurf - a mixture of DPPC with hexadecanol and
tyloxapol added as spreading agents, Pumactant (Artificial Lung Expanding
Compound or ALEC) - a mixture of DPPC and PG, KL-4 - composed of
DPPC, palmitoyl-oleoyl phosphatidylglycerol, and palmitic acid, combined
31
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
with a 21 amino acid synthetic peptide that mimics the structural
characteristics of SP-B, Venticute DPPC, PG, palmitic acid and
recombinant SP-C, Alveofact - extracted from cow lung lavage fluid,
Curosurf - extracted from material derived from minced pig lung, Infasurf -
extracted from calf lung lavage fluid, and Survanta - extracted from minced
cow lung with additional DPPC, palmitic acid and tripalmitin. Exo surf,
Curosurf, Infasurf, and Survanta are the surfactants currently FDA approved
for use in the U.S.
The pharmaceutical carrier may also include one or more stabilizing
agents or dispersing agents. The pharmaceutical carrier may also include one
or more pH adjusters or buffers. Suitable buffers include organic salts
prepared from organic acids and bases, such as sodium citrate or sodium
ascorbate. The pharmaceutical carrier may also include one or more salts,
such as sodium chloride or potassium chloride.
Dry powder formulations are typically prepared by blending one or
more nanoparticle carriers with one or more pharmaceutically acceptable
carriers. Optionally, additional active agents may be incorporated into the
mixture as discussed below. The mixture is then formed into particles
suitable for pulmonary administration using techniques known in the art,
such as lyophilization, spray drying, agglomeration, spray coating,
coacervation, low temperature casting, milling (e.g., air-attrition milling
(jet
milling), ball milling), high pressure homogenization, and/or supercritical
fluid crystallization.
An appropriate method of particle formation can be selected based on
the desired particle size, particle size distribution, and particle morphology
desired for the formulation. In some cases, the method of particle formation
is selected so as to produce a population of particles with the desired
particle
size, particle size distribution for pulmonary administration. Alternatively,
the method of particle formation can produce a population of particles from
which a population of particles with the desired particle size, particle size
distribution for pulmonary administration is isolated, for example by sieving.
It is known in the art that particle morphology affects the depth of
penetration of a particle into the lung. Accordingly, dry powder formulations
32
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
is processed into particles having the appropriate mass median aerodynamic
diameter (MMAD), tap density, and surface roughness to achieve delivery of
the one or more active agents to the desired region(s) of the lung. For
example, preferred particle morphologies for delivery to the deep lung are
known in the art, and are described, for example, in U.S. Patent No.
7,052,678 to Vanbever, et al.
Particles having a mass median aerodynamic diameter (MMAD) of
greater than about 5 microns generally do not reach the lung; instead, they
tend to impact the back of the throat and are swallowed. Particles having
diameters of about 3 to about 5 microns are small enough to reach the upper-
to mid-pulmonary region (conducting airways), but may be too large to reach
the alveoli. Smaller particles, (i.e., about 0.5 to about 3 microns), are
capable of efficiently reaching the alveolar region. Particles having
diameters smaller than about 0.5 microns can also be deposited in the
alveolar region by sedimentation.
The precise particle size range effective to achieve delivery to the
alveolar region will depend on several factors, including the tap density of
particles being delivered. Generally speaking, as tap density decreases, the
MMAD of particles capable of efficiently reaching the alveolar region of the
lungs increases. Therefore, in cases of particles with low tap densities,
particles having diameters of about 3 to about 5 microns, about 5 to about 7
microns, or about 7 to about 9.5 microns can be efficiently delivered to the
lungs. The preferred aerodynamic diameter for maximum deposition within
the lungs can be calculated. See, for example, U.S. Patent No. 7,052,678 to
Vanbever, et al.
Microparticles cannot diffuse through mucus even if their surface is
muco-inert. However, mucus-penetrating particles can be encapsulated in
microparticles to impact upper lung, and subsequently release the
nanoparticles. In some cases, the particles are spherical or ovoid in shape.
The particles can have a smooth or rough surface texture. The particles may
also be coated with a polymer or other suitable material to control release of
one or more active agents in the lungs.
33
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
Dry powder formulations can be administered as dry powder using
suitable methods known in the art. Alternatively, the dry powder
formulations can be suspended in the liquid formulations described below,
and administered to the lung using methods known in the art for the delivery
of liquid formulations.
2. Liquid Formulations
Liquid formulations contain one or more nanoparticle carriers
suspended in a liquid pharmaceutical carrier. Suitable liquid carriers
include,
but are not limited to water, saline, and other physiologically acceptable
aqueous solutions containing salts and/or buffers, such as phosphate buffered
saline (PBS), Ringer's solution, and isotonic sodium chloride, or any other
aqueous solution acceptable for administration to an animal or human, which
is adjusted to the desired hypotonicity as indicated by the osmotically driven
flow of water through the epithelium from the luminal (mucosal) surface to
the serosal surface. At certain mucosa' surfaces, such as the colon,
"hyperosmolal" fluid carriers (defined in the conventional sense, with respect
to blood osmolality) may indeed by hypotonic in the colon and induce fluid
absorption by the epithelium. Indeed, isotonic formulations have not yet been
defined in the lung, and in certain disease states such as Cystic Fibrosis,
the
osmolality of lung fluid is hyperosmolal (higher than blood osmolality).
Preferably, liquid formulations are mildly hypotonic relative to
physiological fluids and of approximately the same pH, ranging e.g., from
about pH 4.0 to about pH 7.4, more preferably from about pH 6.0 to pH 7Ø
The liquid pharmaceutical carrier can include one or more physiologically
compatible buffers, such as a phosphate buffers. One skilled in the art can
readily determine a suitable saline content and pH for an aqueous solution
for pulmonary administration.
Liquid formulations may include one or more suspending agents,
such as cellulose derivatives, sodium alginate, polyvinylpyrrolidone, gum
tragacanth, or lecithin. Liquid formulations may also include one or more
preservatives, such as ethyl or n-propyl p-hydroxybenzoate.
In some cases the liquid formulation may contain one or more
solvents that are low toxicity organic (i.e. nonaqueous) class 3 residual
34
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
solvents, such as ethanol, acetone, ethyl acetate, tetrahydofuran, ethyl
ether,
and propanol. These solvents can be selected based on their ability to readily
aerosolize the formulation. Any such solvent included in the liquid
formulation should not detrimentally react with the one or more active agents
present in the liquid formulation. The solvent should be sufficiently volatile
to enable formation of an aerosol of the solution or suspension. Additional
solvents or aerosolizing agents, such as a freon, alcohol, glycol, polyglycol,
or fatty acid, can also be included in the liquid formulation as desired to
increase the volatility and/or alter the aerosolizing behavior of the solution
or
suspension.
Liquid formulations may also contain minor amounts of polymers,
surfactants, or other excipients well known to those of the art. In this
context, "minor amounts" means no excipients are present that might
adversely affect uptake of the one or more active agents in the lungs.
3. Aerosol Formulations
The dry powder and liquid formulations described above can be used
to form aerosol formulations for pulmonary administration. Aerosols for the
delivery of therapeutic agents to the respiratory tract are known in the art.
The term aerosol as used herein refers to any preparation of a fine mist of
solid or liquid particles suspended in a gas. In some cases, the gas may be a
propellant; however, this is not required. Aerosols may be produced using a
number of standard techniques, including as ultrasonication or high pressure
treatment.
In some cases, a device is used to administer the foimulations to the
lungs. Suitable devices include, but are not limited to, dry powder inhalers,
pressurized metered dose inhalers, nebulizers, and electrohydrodynamic
aerosol devices. Inhalation can occur through the nose and/or the mouth of
the patient. Administration can occur by self-administration of the
formulation while inhaling or by administration of the formulation via a
respirator to a patient on a respirator.
B. Topical and Ophthalmic Formulations
Topical or enteral formulations can be prepared as aqueous
compositions using techniques is known in the art. Typically, such
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
compositions can be prepared as solutions or suspensions; solid forms
suitable for using to prepare solutions or suspensions upon the addition of a
reconstitution medium prior to injection; emulsions, such as water-in-oil
(w/o) emulsions, oil-in-water (o/w) emulsions, and microemulsions thereof,
liposomes, emulsomes, sprays, gels, creams or ointments.
The carrier can be a solvent or dispersion medium containing, for
example, water, ethanol, one or more polyols (e.g., glycerol, propylene
glycol, and liquid polyethylene glycol), oils, such as vegetable oils (e.g.,
peanut oil, corn oil, sesame oil, etc.), and combinations thereof. The proper
fluidity can be maintained, for example, by the use of a coating, such as
lecithin, by the maintenance of the required particle size in the case of
dispersion and/or by the use of surfactants. In many cases, it will be
preferable to include agents, for example, sugars or sodium chloride, to
adjust the tonicity.
Solutions and dispersions of the active compounds as the free acid or
base or pharmacologically acceptable salts thereof can be prepared in water
or another solvent or dispersing medium suitably mixed with one or more
pharmaceutically acceptable excipients including, but not limited to,
surfactants, dispersants, emulsifiers, pH modifying agents, and combination
thereof.
Suitable surfactants may be anionic, cationic, amphotetic or nonionic
surface active agents. Suitable anionic surfactants include, but are not
limited
to, those containing carboxylate, sulfonate and sulfate ions. Examples of
anionic surfactants include sodium, potassium, ammonium of long chain
alkyl sulfonates and alkyl aryl sulfonates such as sodium dodecylbenzene
sulfonate; dialkyl sodium sulfosuccinates, such as sodium dodecylbenzene
sulfonate; dialkyl sodium sulfosuccinates, such as sodium bis-(2-
ethylthioxyl)-sulfosuccinate; and alkyl sulfates such as sodium lauryl
sulfate.
Cationic surfactants include, but are not limited to, quaternary ammonium
compounds such as benzalkonium chloride, benzethonium chloride,
cetrimonium bromide, stearyl dimethylbenzyl ammonium chloride,
polyoxyethylene and coconut amine. Examples of nonionic surfactants
include ethylene glycol monostearate, propylene glycol myristate, glyceryl
36
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
monostearate, glyceryl stearate, polyglycery1-4-oleate, sorbitan acylate,
sucrose acylate, PEG-150 laurate, PEG-400 monolaurate, polyoxyethylene
monolaurate, polysorbates, polyoxyethylene octylphenylether, PEG-1000
cetyl ether, polyoxyethylene tridecyl ether, polypropylene glycol butyl ether,
Poloxamer 401, stearoyl monoisopropanolamide, and polyoxyethylene
hydrogenated tallow amide. Examples of amphoteric surfactants include
sodium N-dodecyl-beta-alanine, sodium N-lauryl-beta-iminodipropionate,
myristoamphoacetate, lauryl betaine and lauryl sulfobetaine.
The formulation can contain a preservative to prevent the growth of
microorganisms. Suitable preservatives include, but are not limited to,
parabens, chlorobutanol, phenol, sorbic acid, and thimerosal. The
formulation may also contain an antioxidant to prevent degradation of the
active agent(s).
The founulation is typically buffered to a pH of 3-8 for
administration upon reconstitution. Suitable buffers include, but are not
limited to, phosphate buffers, acetate buffers, and citrate buffers.
Water soluble polymers are often used in pharmaceutical
formulations. Suitable water-soluble polymers include, but are not limited
to, polyvinylpyrrolidone, dextran, carboxymethylcellulose, and polyethylene
glycol.
Sterile solutions can be prepared by incorporating the active
compounds in the required amount in the appropriate solvent or dispersion
medium with one or more of the excipients listed above, as required,
followed by filtered sterilization. Generally, dispersions are prepared by
incorporating the various sterilized active ingredients into a sterile vehicle
which contains the basic dispersion medium and the required other
ingredients from those listed above. In the case of sterile powders for the
preparation of sterile injectable solutions, the preferred methods of
preparation are vacuum-drying and freeze-drying techniques which yield a
powder of the active ingredient plus any additional desired ingredient from a
previously sterile-filtered solution thereof. The powders can be prepared in
such a manner that the particles are porous in nature, which can increase
dissolution of the particles. Methods for making porous particles are well
37
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
known in the art.
Pharmaceutical formulations for ocular administration are preferably
in the form of a sterile aqueous solution or suspension of particles formed
from one or more polymer-drug conjugates. Acceptable solvents include, for
example, water, Ringer's solution, osmolar (PBS), and iso-osmolar sodium
chloride solution, which are then adjusted to the desired hypotonicity for the
eye as determined using MPP to observe osmotically-induced flow of water
(tear fluid). The formulation may also be a sterile solution, suspension, or
emulsion in a nontoxic, parenterally acceptable diluent or solvent such as
1,3-butanediol.
In some instances, the formulation is distributed or packaged in a
liquid or semi-solid form such as a solution (eye drops), suspension, gel,
cream or ointment. Alternatively, formulations for ocular administration can
be packed as a solid, obtained, for example by lyophilization of a suitable
liquid formulation. The solid can be reconstituted with an appropriate carrier
or diluent prior to administration.
Solutions, suspensions, or emulsions for ocular administration may be
buffered with an effective amount of buffer necessary to maintain a pH
suitable for ocular administration. Suitable buffers are well known by those
skilled in the art and some examples of useful buffers are acetate, borate,
carbonate, citrate, and phosphate buffers. Solutions, suspensions, or
emulsions for ocular administration may also contain one or more tonicity
agents to adjust the tonicity of the formulation to be in the moderately
hypotonic range. Suitable tonicity agents are well known in the art and some
examples include glycerin, mannitol, sorbitol, sodium chloride, and other
electrolytes.
Solutions, suspensions, or emulsions for ocular administration may
also contain one or more preservatives to prevent bacterial contamination of
the ophthalmic preparations. Suitable preservatives are known in the art, and
include polyhexamethylenebiguanidine (PHMB), benzalkonium chloride
(BAK), stabilized oxychloro complexes (otherwise known as Purite6),
phenylmercuric acetate, chlorobutanol, sorbic acid, chlorhexidine, benzyl
alcohol, parabens, thimerosal, and mixtures thereof.
38
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
Solutions, suspensions, or emulsions for ocular administration may
also contain one or more excipients known in the art, such as dispersing
agents, wetting agents, and suspending agents.
In still other embodiments, the nanoparticles are formulated for
topical administration to mucosa. Suitable dosage forms for topical
administration include creams, ointments, salves, sprays, gels, lotions, and
emulsions. The compositions may contain one or more chemical penetration
enhancers, membrane permeability agents, membrane transport agents,
emollients, surfactants, stabilizers, and combination thereof.
In some embodiments, the nanoparticles can be administered as a liquid
formulation, such as a solution or suspension, a semi-solid formulation, such
as a gel, a lotion or an ointment, or a solid formulation. A "gel" is a
colloid in which the dispersed phase has combined with the continuous phase
to produce a semisolid material, such as jelly.
In some embodiments, the nanoparticles are formulated as liquids,
including solutions and suspensions, such as eye drops or as a semi-solid
formulation, such as ointment or lotion for topical application to mucosa,
such as the eye or vaginally or rectally.
The formulation may contain one or more excipients, such as
emollients, surfactants, and emulsifiers.
"Emollients" are an externally applied agent that softens or soothes
skin and are generally known in the art and listed in compendia, such as the
"Handbook of Pharmaceutical Excipients", 4th Ed., Pharmaceutical Press,
2003. These include, without limitation, almond oil, castor oil, ceratonia
extract, cetostearoyl alcohol, cetyl alcohol, cetyl esters wax, cholesterol,
cottonseed oil, cyclomethicone, ethylene glycol palmitostearate, glycerin,
glycerin monostearate, glyceryl monooleate, isopropyl myristate, isopropyl
palmitate, lanolin, lecithin, light mineral oil, medium-chain triglycerides,
mineral oil and lanolin alcohols, petrolatum, petrolatum and lanolin alcohols,
soybean oil, starch, stearyl alcohol, sunflower oil, xylitol and combinations
thereof. In one embodiment, the emollients are ethylhexylstearate and
ethylhexyl palmitate.
39
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
"Surfactants" are surface-active agents that lower surface tension and
thereby increase the emulsifying, foaming, dispersing, spreading and wetting
properties of a product. Suitable non-ionic surfactants include emulsifying
wax, glyceryl monooleate, polyoxyethylene alkyl ethers, polyoxyethylene
castor oil derivatives, polysorbate, sorbitan esters, benzyl alcohol, benzyl
benzoate, cyclodextrins, glycerin monostearate, poloxamer, povidone and
combinations thereof. In one embodiment, the non-ionic surfactant is stearyl
alcohol.
"Emulsifiers" are surface active substances which promote the
suspension of one liquid in another and promote the formation of a stable
mixture, or emulsion, of oil and water. Common emulsifiers are: metallic
soaps, certain animal and vegetable oils, and various polar compounds.
Suitable emulsifiers include acacia, anionic emulsifying wax, calcium
stearate, carbomers, cetostearyl alcohol, cetyl alcohol, cholesterol,
diethanolamine, ethylene glycol palmitostearate, glycerin monostearate,
glyceryl monooleate, hydroxpropyl cellulose, hypromellose, lanolin,
hydrous, lanolin alcohols, lecithin, medium-chain triglycerides,
methylcellulose, mineral oil and lanolin alcohols, monobasic sodium
phosphate, monoethanolamine, nonionic emulsifying wax, oleic acid,
poloxamer, poloxamers, polyoxyethylene alkyl ethers, polyoxyethylene
castor oil derivatives, polyoxyethylene sorbitan fatty acid esters,
polyoxyethylene stearates, propylene glycol alginate, self-emulsifying
glyceryl monostearate, sodium citrate dehydrate, sodium lauryl sulfate,
sorbitan esters, stearic acid, sunflower oil, tragacanth, triethanolamine,
xanthan gum and combinations thereof. In one embodiment, the emulsifier
is glycerol stearate.
Suitable classes of penetration enhancers are known in the art and
include, but are not limited to, fatty alcohols, fatty acid esters, fatty
acids,
fatty alcohol ethers, amino acids, phospholipids, lecithins, cholate salts,
enzymes, amines and amides, complexing agents (liposomes, cyclodextrins,
modified celluloses, and diimides), macrocyclics, such as macrocylic
lactones, ketones, and anhydrides and cyclic ureas, surfactants, N-methyl
pyrrolidones and derivatives thereof, DMSO and related compounds, ionic
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
compounds, azone and related compounds, and solvents, such as alcohols,
ketones, amides, polyols (e.g., glycols). Examples of these classes are
known in the art.
An "oil" is a composition containing at least 95% wt of a lipophilic
substance. Examples of lipophilic substances include but are not limited to
naturally occurring and synthetic oils, fats, fatty acids, lecithins,
triglycerides
and combinations thereof.
A "continuous phase" refers to the liquid in which solids are
suspended or droplets of another liquid are dispersed, and is sometimes
called the external phase. This also refers to the fluid phase of a colloid
within which solid or fluid particles are distributed. If the continuous phase
is water (or another hydrophilic solvent), water-soluble or hydrophilic drugs
will dissolve in the continuous phase (as opposed to being dispersed). In a
multiphase formulation (e.g., an emulsion), the discreet phase is suspended
or dispersed in the continuous phase.
An "emulsion" is a composition containing a mixture of non-miscible
components homogenously blended together. In particular embodiments, the
non-miscible components include a lipophilic component and an aqueous
component. An emulsion is a preparation of one liquid distributed in small
globules throughout the body of a second liquid. The dispersed liquid is the
discontinuous phase, and the dispersion medium is the continuous phase.
When oil is the dispersed liquid and an aqueous solution is the continuous
phase, it is known as an oil-in-water emulsion, whereas when water or
aqueous solution is the dispersed phase and oil or oleaginous substance is the
continuous phase, it is known as a water-in-oil emulsion. Either or both of
the oil phase and the aqueous phase may contain one or more surfactants,
emulsifiers, emulsion stabilizers, buffers, and other excipients. Preferred
excipients include surfactants, especially non-ionic surfactants; emulsifying
agents, especially emulsifying waxes; and liquid non-volatile non-aqueous
materials, particularly glycols such as propylene glycol. The oil phase may
contain other oily pharmaceutically approved excipients. For example,
materials such as hydroxylated castor oil or sesame oil may be used in the oil
phase as surfactants or emulsifiers.
41
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
An emulsion is a preparation of one liquid distributed in small
globules throughout the body of a second liquid. The dispersed liquid is the
discontinuous phase, and the dispersion medium is the continuous phase.
When oil is the dispersed liquid and an aqueous solution is the continuous
phase, it is known as an oil-in-water emulsion, whereas when water or
aqueous solution is the dispersed phase and oil or oleaginous substance is the
continuous phase, it is known as a water-in-oil emulsion. The oil phase may
consist at least in part of a propellant, such as an HFA propellant. Either or
both of the oil phase and the aqueous phase may contain one or more
surfactants, emulsifiers, emulsion stabilizers, buffers, and other excipients.
Preferred excipients include surfactants, especially non-ionic surfactants;
emulsifying agents, especially emulsifying waxes; and liquid non-volatile
non-aqueous materials, particularly glycols such as propylene glycol. The
oil phase may contain other oily pharmaceutically approved excipients. For
example, materials such as hydroxylated castor oil or sesame oil may be used
in the oil phase as surfactants or emulsifiers.
A sub-set of emulsions are the self-emulsifying systems. These drug
delivery systems are typically capsules (hard shell or soft shell) comprised
of
the drug dispersed or dissolved in a mixture of surfactant(s) and lipophilic
liquids such as oils or other water immiscible liquids. When the capsule is
exposed to an aqueous environment and the outer gelatin shell dissolves,
contact between the aqueous medium and the capsule contents instantly
generates very small emulsion droplets. These typically are in the size range
of micelles or nanoparticles. No mixing force is required to generate the
emulsion as is typically the case in emulsion formulation processes.
A "lotion" is a low- to medium-viscosity liquid foimulation. A lotion
can contain finely powdered substances that are in soluble in the dispersion
medium through the use of suspending agents and dispersing agents.
Alternatively, lotions can have as the dispersed phase liquid substances that
are immiscible with the vehicle and are usually dispersed by means of
emulsifying agents or other suitable stabilizers. In one embodiment, the
lotion is in the form of an emulsion having a viscosity of between 100 and
1000 centistokes. The fluidity of lotions permits rapid and uniform
42
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
application over a wide surface area. Lotions are typically intended to dry on
the skin leaving a thin coat of their medicinal components on the skin's
surface.
A "cream" is a viscous liquid or semi-solid emulsion of either the
"oil-in-water" or "water-in-oil type". Creams may contain emulsifying
agents and/or other stabilizing agents. In one embodiment, the formulation is
in the form of a cream having a viscosity of greater than 1000 centistokes,
typically in the range of 20,000-50,000 centistokes. Creams are often time
preferred over ointments as they are generally easier to spread and easier to
remove.
The difference between a cream and a lotion is the viscosity, which is
dependent on the amount/use of various oils and the percentage of water
used to prepare the formulations. Creams are typically thicker than lotions,
may have various uses and often one uses more varied oils/butters,
depending upon the desired effect upon the skin. In a cream formulation, the
water-base percentage is about 60-75 % and the oil-base is about 20-30 % of
the total, with the other percentages being the emulsifier agent,
preservatives
and additives for a total of 100 %.
An "ointment" is a semisolid preparation containing an ointment base
and optionally one or more active agents. Examples of suitable ointment
bases include hydrocarbon bases (e.g., petrolatum, white petrolatum, yellow
ointment, and mineral oil); absorption bases (hydrophilic petrolatum,
anhydrous lanolin, lanolin, and cold cream); water-removable bases (e.g.,
hydrophilic ointment), and water-soluble bases (e.g., polyethylene glycol
ointments). Pastes typically differ from ointments in that they contain a
larger percentage of solids. Pastes are typically more absorptive and less
greasy that ointments prepared with the same components.
A "gel" is a semisolid system containing dispersions of small or large
molecules in a liquid vehicle that is rendered semisolid by the action of a
thickening agent or polymeric material dissolved or suspended in the liquid
vehicle. The liquid may include a lipophilic component, an aqueous
component or both. Some emulsions may be gels or otherwise include a gel
component. Some gels, however, are not emulsions because they do not
43
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
contain a homogenized blend of immiscible components. Suitable gelling
agents include, but are not limited to, modified celluloses, such as
hydroxypropyl cellulose and hydroxyethyl cellulose; Carbopol
homopolymers and copolymers; and combinations thereof. Suitable solvents
in the liquid vehicle include, but are not limited to, diglycol monoethyl
ether;
alklene glycols, such as propylene glycol; dimethyl isosorbide; alcohols,
such as isopropyl alcohol and ethanol. The solvents are typically selected for
their ability to dissolve the drug. Other additives, which improve the skin
feel and/or emolliency of the formulation, may also be incorporated.
Examples of such additives include, but are not limited, isopropyl myristate,
ethyl acetate, C12-C15 alkyl benzoates, mineral oil, squalane, cyclomethicone,
capric/caprylic triglycerides, and combinations thereof.
Foams consist of an emulsion in combination with a gaseous
propellant or gas-emitting component..
Buffers are used to control pH of a composition. Preferably, the
buffers buffer the composition from a pH of about 4 to a pH of about 7.5,
more preferably from a pH of about 4 to a pH of about 7, and most
preferably from a pH of about 5 to a pH of about 7.
D. Enteral Formulations
Suitable oral dosage forms include tablets, capsules, solutions,
suspensions, syrups, and lozenges. Tablets can be made using compression
or molding techniques well known in the art. Gelatin or non-gelatin capsules
can prepared as hard or soft capsule shells, which can encapsulate liquid,
solid, and semi-solid fill materials, using techniques well known in the art.
Formulations may be prepared using one or more pharmaceutically
acceptable excipients, including diluents, preservatives, binders, lubricants,
disintegators, swelling agents, fillers, stabilizers, and combinations
thereof.
Excipients, including plasticizers, pigments, colorants, stabilizing
agents, and glidants, may also be used to form coated compositions for
enteral administration. Delayed release dosage formulations may be
prepared as described in standard references such as "Pharmaceutical dosage
form tablets", eds. Liberman et. al. (New York, Marcel Dekker, Inc., 1989),
"Remington ¨ The science and practice of pharmacy", 20th ed., Lippincott
44
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
Williams & Wilkins, Baltimore, MD, 2000, and "Pharmaceutical dosage
forms and drug delivery systems", 6th Edition, Ansel et al., (Media, PA:
Williams and Wilkins, 1995). These references provide information on
excipients, materials, equipment and process for preparing tablets and
capsules and delayed release dosage forms of tablets, capsules, and granules.
The nanoparticles may be coated, for example to delay release once
the particles have passed through the acidic environment of the stomach.
Examples of suitable coating materials include, but are not limited to,
cellulose polymers such as cellulose acetate phthalate, hydroxypropyl
cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose
phthalate and hydroxypropyl methylcellulose acetate succinate; polyvinyl
acetate phthalate, acrylic acid polymers and copolymers, and methacrylic
resins that are commercially available under the trade name EUDRAGITO
(Roth Pharma, Westerstadt, Germany), zein, shellac, and polysaccharides.
Diluents, also referred to as "fillers," are typically necessary to
increase the bulk of a solid dosage form so that a practical size is provided
for compression of tablets or formation of beads and granules. Suitable
diluents include, but are not limited to, dicalcium phosphate dihydrate,
calcium sulfate, lactose, sucrose, mannitol, sorbitol, cellulose,
microcrystalline cellulose, kaolin, sodium chloride, dry starch, hydrolyzed
starches, pregelatinized starch, silicone dioxide, titanium oxide, magnesium
aluminum silicate and powdered sugar.
Binders are used to impart cohesive qualities to a solid dosage
formulation, and thus ensure that a tablet or bead or granule remains intact
after the formation of the dosage forms. Suitable binder materials include,
but are not limited to, starch, pregelatinized starch, gelatin, sugars
(including
sucrose, glucose, dextrose, lactose and sorbitol), polyethylene glycol, waxes,
natural and synthetic gums such as acacia, tragacanth, sodium alginate,
cellulose, including hydroxypropylmethylcellulose, hydroxypropylcellulose,
ethylcellulose, and veegum, and synthetic polymers such as acrylic acid and
methacrylic acid copolymers, methacrylic acid copolymers, methyl
methacrylate copolymers, aminoalkyl methacrylate copolymers, polyacrylic
acid/polymethacrylic acid and polyvinylpyrrolidone.
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
Lubricants are used to facilitate tablet manufacture. Examples of
suitable lubricants include, but are not limited to, magnesium stearate,
calcium stearate, stearic acid, glycerol behenate, polyethylene glycol, talc,
and mineral oil.
Disintegrants are used to facilitate dosage form disintegration or
"breakup" after administration, and generally include, but are not limited to,
starch, sodium starch glycolate, sodium carboxymethyl starch, sodium
carboxymethylcellulose, hydroxypropyl cellulose, pregelatinized starch,
clays, cellulose, alginine, gums or cross linked polymers, such as cross
linked PVP (Polyplasdone XL from GAF Chemical Corp).
Stabilizers are used to inhibit or retard drug decomposition reactions
that include, by way of example, oxidative reactions. Suitable stabilizers
include, but are not limited to, antioxidants, butylated hydroxytoluene
(BHT); ascorbic acid, its salts and esters; Vitamin E, tocopherol and its
salts;
sulfites such as sodium metabisulphite; cysteine and its derivatives; citric
acid; propyl gallate, and butylated hydroxyanisole (BHA).
IV. Methods of making MPPs
Techniques for making nanoparticles are known in the art and
include, but are not limited to, solvent evaporation, solvent removal, spray
drying, phase inversion, low temperature casting, and nanoprecipitation.
Suitable methods of particle formulation are briefly described below.
Pharmaceutically acceptable excipients, including pH modifying agents,
disintegrants, preservatives, and antioxidants, can optionally be incorporated
into the particles during particle formation. As described above, one or more
additional active agents can also be incorporated into the nanoparticle during
particle formation.
V. Methods of using MPP-Hypotonic Formulations
The formulations containing the particles are administered to a
mucosal surface in an effective amount of therapeutic to alleviate one or
more symptoms, wherein the formulation is hypotonic to enhance uptake of
the particles through the mucosa without causing toxicity. This may be
using a single-administration sterile packaging containing a solution or
suspension such as eye drops or an applicator for a dry powder, gel,
46
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
ointment, cream or lotion for topical administration to the ocular area, to a
region of the mouth (buccal, sublingual), vagina, rectum or aerosol, or it
could be formulated for oral administration.
The present invention will be further understood by reference to the
following non-limiting examples.
Examples
Examples 1-6 demonstrate preparation and characterization of
mucous penetrating particles ("MPPs"). Examples 7-9 demonstrate the
effect of hypotonic formulations on uptake and toxicity of MPPs
administered to mucosa' tissue.
Materials and Methods
Cholic acid sodium salt, TWEEN 20, TWEENO 80,
hexadecyltrimethylammonium bromide (CTAB), dioctyl sulfosuccinate
sodium (DSS), Polyoxyl 35 hydrogenated castor oil (Cremophor EL) and D-
cc-tocopherol polyethylene glycol 1000 (Vitamin E-TPGS), were purchased
from Sigma (St. Louis, MO).
Poly(vinyl alcohol) (Mw----25kDa with 88% hydrolysis and 6kDa with
80% hydrolysis),and poly(ethylerie-maleic anhydride, 1:1 molar ratio) with
Mw---4001(Da were bought from PolySciences (Warrington, PA).
Sugar ester D1216 (SE) was a gift from Mitsubishi-Kagaku Foods
Co. (Tokyo, Japan).
Alexa Fluor 555 cadaverine was purchased from Invitrogen (Grand
Island, NY).
Poly(lactic-co-glycolic acid) (PLGA; LA:GA 50:50) with inherent
viscosity of 0.15-0.25 dL/g (MW approximately 151(Da) was purchased from
Lakeshore Biomaterials (Birmingham, AL). PLGA(LA:GA 50:50)-PEG
copolymers with PEG MW of 10, 5,2 and 1 kDa, PLA-PEG5k and PCL-
PEG5k were custom-synthesized by the jinan Daigang Biomaterial Co., Ltd,
(Jinan, China) and characterized by 1H NMR and gel permeation
chromatography (GPC). A Shimadzu apparatus equipped with a refractive
index detector and two Waters Styragel HR4 and HR5 columns were used.
The analysis was performed at 35 C, using tetrahydrofuran (THF) as the
eluent, at a flow rate of 0.5 ml/min. GPC was calibrated with polystyrene
47
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
standards (Sigma, St. Louis, MO).
The chemical composition and molecular weight (MW) of PLGA-
PEG block copolymer were characterized by 11-1 NMR. Polymers were
dissolved in CDC13 and II-I NMR spectra were recorded using a Bruker 400
REM instrument at 400 MHz. The Ili NMR spectra for copolymers in CDC13
are shown in Figure 3. Peaks of CH (5.22 ppm) from LA unit, CH2 (4.83
ppm) from GA unit, and CH2CH2 (3.65 ppm) from ethylene oxide unit were
integrated, where 15.22, 14.83, '365 are the integral intensities of the peaks
at
5.22, 4.83 and 3.65ppm, respectively. Ratio of LA:GA was estimated as 15.22
: (14.83/2).
The MW of PLGA-PEG was estimated as follows:
(13.65/4)/(14.83/2)=(MWpE0/44)/(MWGA/58)
(13.65/4)/(15.22/1)=(MWpEG/44)/(MWLA/72)
MWK,GA-PEG=MWPEG+(\4WGA+MWLA), where MWpEG is 1, 2, 5 and 10kDa.
Similarly, the molecular weight of PLA-PEG and PCL-PEG were
estimated as follows:
(13.65/4)/(15.22/1)=(MWPEG/44)/(MWLA/72)
MWPLA-PEG=MWPEG+MWIA;
(13 J55/4)4(14.064" 12,30/4)77-(MWpEG/44)/(MWai1 14)
MWKL-pEo=MWpEo+MWa,),
where MWpEG is 5 kDa, 14,06 abd 12,31 are the integral intensities of the
peaks from PCL at 4.06 and 2.31 ppm, respectively.
Characteristics of various PEG-containing block copolymers are
shown in Table 1.
48
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
Table 1: Characteristics of PEG-containing block copolymers
Block polymer PEG LA:G PEG Mn1 Mn[di Mw1d1 PDItdi
[kDa] Ar83 content lik.Dal [kDal [kDa.]
[b] [voi
PLGA- 10 54:46 21.61
) 46.3 23.6 38.3 1.62
PEGlOk
PLGA-PEG5k 5 51:49 6.0 83.0 39.2 57.8 1.48
PLGA-PEG2k 2 52:48 6.3 31.8 19.0 27.7 1.46
PLGA-PEG 1 k 1 61:39 5.7 17.7 19.3 27.6 1.43
PLA-PEG5k 5 100:0 5.3 94.9 64.7 87.4 1.35
PCL-PEG5k 5 6.4 77.9 54.6 73.6 1.35
ral The molar ratio of LA:GA was measured by comparing the 1H NMR
integral intensity at 5.22ppm (-CH- on lactide), 1.59ppm (-CH3 on lactide)
and 4.83ppm (-CH2- on glycolide).
[11 PEG content in the block copolymers were determined by 1H NMR.
PLGA-PEG molecular weight (Mn) was determined by 1H NMR through
comparing the integral at 5.22ppm (-CH- in lactide), 1.59ppm (-CH3 on
lactide), 4.83ppm (-CH2- in glycolide) and 3.65ppm (-CH2CH2- in PEG) and
by taking into account of the known Mn of PEG. For PCL-PEG, integrals at
4.06ppm (-0-CH2-) and 2.31 ppm (-CH2-00-) were analyzed.
Mn, Mw and polydispersity (PD I) were measured by GPC.
tel PLGA-PEG10kDa nanoparticles were made from the blending of
PLGA15kDa with PLGA-PEG10kDa (21.6% PEG content) with overall
PEG content in the nanoparticles at 6 wt%.
The total PEG content within nanoparticles was determined by 1H
NMR using Braker 400 REM instrument at 400 mHz. The freeze-dried
nanoparticles were accurately weighed and dissolved in CDC13 containing 1
wt% hexadeuterodimethyl sulfoxide (TMS) as internal standard. The PEG
content was determined by comparing to a PEG 5kDa calibration curve
achieved from 11 NMR spectra using TMS as internal standard.
49
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
The tracking of fluorescently labeled nanoparticles in fresh human
cervicovaginal mucus (CVM) was performed. Briefly, 0.6 pi of nanoparticles
at suitable dilution was mixed into 20 ill mucus and incubated for 1 hour
prior to microscopy. Movies were captured at a temporal resolution of 66.7
ms using a silicon-intensified target camera (VE-1000, Dage-MTI) mounted
on an inverted epifluorescence microscope equipped with 100x oil-
immersion objective lens. Trajectories for n>150 particles per experiment
were extracted using MetaMorph software (Universal Imaging). Tracking
movies (20s) were analyzed using metamorph software (Universal Imaging,
Glendale, WI). Time averaged mean square displacement (MSD) and
effective diffusivity for each particle were calculated as a function of time
scale. Three experiments were performed for each condition. A one tailed,
unequal variance Student's t-test was used to evaluate significance (P <0.05).
The ITC experiments were performed at 25 C, using a VP-ITC
microcalorimeter (MicroCal Inc., USA). Experiments were performed by
injecting 2 mg/ml solution of mucin in DI water into 2mL sample cell
containing nanoparticles with different PEG surface density at a
concentration of 1 mg/ml in water with a stirring speed of 481 rpm. A total
28 injections were performed with a spacing of s and a reference power of
[waifs. The first injection of 2 ul mucin solution was followed by 27
injections of 10 1 of mucin solution. Binding isotherms were plotted and
analyzed using Origin software, where the ITC measurements were fit to a
one-site binding model. Stochoimetry was applied to calculate the binding
content of mucin on nanoparticle surface, presented as mg mucin per m2.
Example 1. Preparation of nanoparticles
Materials and Methods
Biodegradable nanoparticles were prepared by either o/w single
emulsion or w/o/w double emulsion method as described in R. C. Mundargi
et al, J Control. Release 125, 193 (2008), M. Li et al., Int. J Pharm. 363, 26
(2008), C. E. Astete and C. M. Sabliov, J. Biomater. Sc!. Polymer Ed. 17,
247 (2006), and R. A. JaM, Biomaterials, 21, 2475 (2000).
Nanoparticles were characterized for size, surface property and drug
loading (for drug encapsulated nanoparticles). The displacements of
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
nanoparticles were tracked in fresh, undiluted human CVM using multiple
particle tracking.
Nanoparticles prepared with different amounts of PEG
PLGA-PEG nanoparticles were prepared with varying target PEG
contents (0, 2, 3, 5, 8, 10 and 25 wt%, referred to as PLGA, PLGA-PEG2%,
PLGA-PEG3%, PLGA-PEG5%, PLGA-PEG8%, PLGA-PEG10% and
PLGA-PEG25%) using emulsification. The PEG molecular weight 5 kDa
was selected since at the same PEG content, 6wt% PLGA-PEG nanoparticles
with PEG ranging from 1 kDa to 10 kDa all can rapidly penetrate mucus.
The target PEG contents were controlled by varying the ratio of PLGA and
PLGA-PEG during the preparation of nanoparticles. Particle sizes of
nanoparticles were controlled to around 100 nm by tuning polymer
concentration and emulsification procedure, and all nanoparticles exhibited
mono-dispersed diameter with small polydispersity index (less than 0.1)
under dynamic light scattering. The nanoparticles were spherically shaped
based on IBM study, and PLGA-PEG25% nanoparticles with the highest
target PEG content showed less contrast at particle boundaries which
probably resulted from the high content of lower electron-density PEG
located at the surface.
Results
Table 2 shows the characteristics of the particles prepared as
described above.
51
CA 02863632 2014-08-01
WO 2013/110028 PCT/US2013/022387
Table 2: Nanoparticle Characteristics
Target PEG Diameter [nm] PDI fal (-potential a [bi Dõ,//).[cl
content (wt%) Ea] [mV]
25 9115 0.094 -2.710.7 0.89 6.0
11717 0.097 -2.410.6 0.80 8.7
8 11618 0.068 -4.310.9 0.81 7.7
5 10616 0.085 -7.010.7 0.78 17
3 10116 0.078 -1010.1 0.53 142
2 9116 0.075 -2011.4 0.31 4,000
0 14416 0.056 -7212.2 0.13 38,000
fa] Diameter and polydispersity index (PDI) of nanoparticles are measured by
the dynamic laser scattering.
5 [b] The transport rate also can be reflected by the slope a of double
logarithmic MSD versus time scale plots (a =1 represents unobstructed
Brownian transport whereas smaller a reflects increased obstruction to
particle movement.)
Ee3 Ratios of the ensemble average diffusion coefficients in mucus (Dm)
10 compared to in water (Dw) for nanoparticles, and effective diffusivity
values
were calculated at a time scale of 1 s.
Data are means SD.
Increasing the target PEG content resulted in a substantial decrease of
nanoparticle surface charge (Table 2), and nearly neutral surface charge
(approximately 4mV) was achieved when PEG contents reached 8wt% and
above. Decreased surface charge reflects the increased surface PEG coverage
because dense PEG coatings can effectively shield the surface charge of
nanoparticles. However, surface charge (zeta-potential) measurement is not
able to provide quantitative information for assessing PEG surface density
with regard to the number of PEG chains on the surface of a particle.
Furthermore, surface charge measurement can be affected by the core
materials and the measurement media.
52
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
11-1 NMR was utilized to directly quantify the PEG surface density on
nanoparticles. As shown in Table 3, surface PEG content on nanoparticles
increases with the increase in the target PEG content. Table 3 shows the
PEG surface density of PLGA-PEG nanoparticles with different PEG
contents. Surface PEG level was detected by II NMR in D20 as compared
to a standard DSS (1 wt%). The total PEG content in nanoparticles was
measured by IFINMR in CDC13 as compared to a standard TMS (1 wt%).
N/A, not applicable.
Table 3: Surface PEG Content on Nanoparticles
Target PEG Total PEG PEG PEG [F/P] [bi
content (wt%) content in the content on surface
whole NP NP surface density [1]
(vvt%) (wt%) (chains/
100=2) [3]
25 13.0 0.3 12.9 1.0 29.7 2.9 6.7 0.7
7.4 0.1 7.2 0.2 19.4 1.3 4.4 0.3
8 6.0 0.3 16.4 1.6 3.710.4
5 3.7 0.1 3.7 0.2 10.4 0.2 2.4 0.04
3 2.5 0.1 2.6 0.1 6.5 0.2 1.5 0.05
2 1.4 0.4 1.40.02 3.3 0.1 0.76 0.02
0 N/A N/A N/A N/A
PEG density [r] means the calculated number of PEG molecules per 100
nm2 by assuming that all PEG chains on surface are full length of PEG 51(Da.
lb] PEG density/full surface coverage pric I Full mushroom coverage [F1
means the number of unconstrained PEG molecules per 100 nm2. (value < 1
indicates mushroom coverage with low PEG density, whereas > 1 represents
brush regime; when the value >>1 represents a dense brush regime with very
high PEG density).
Data (mean SD) are the average of at least three different batches of
samples.
53
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
Example 2: Nanopartieles prepared with different emulsifiers
Materials and Methods
Alexa Fluor 555 cadaverine (AF555) was chemically conjugated to
polymers. Nanoparticles were prepared using emulsification. Typically, a
mixture (total 50 mg) of PLGA-PEG5k and AF555-labeled PLGA-PEG5k
was dissolved in lmL dichloromethane (DCM). The oil phase was poured
into 5mL aqueous solution containing 1% emulsifier under sonication
(VibraCell, Sonics & Materials Inc., Newtown, CT) at 30% amplitude for 2
mins in an ice-water bath to form the oil-in-water emulsion.
The emulsion was poured into another 40mL aqueous phase of
emulsifier solution under magnetic stirring at 700 rpm for at least 3 hours to
allow the solvent to evaporate. The solvent was further evaporated by
placing the solution in a vacuum chamber for 30 mins. The final nanoparticle
suspensions were filtered through lium syringe filter, centrifuged at 20,000 g
for 25 mins and thoroughly washed with water.
Emulsifiers including cholic acid sodium salt (CHA), dioctyl
sulfosuccinate sodium (DSS), hexadecyltrimethyl ammonium bromide
(CTAB), polyvinyl alcohol (PVA), poly(ethylene-maleic anhydride)
(PEMA), Saponin, TWEEN20, TWEEN80 and sugar ester D1216 (SE) were
tested at a concentration of 1% w/v. CHA solutions at 0.01%-0.5% w/v were
also able to make nanoparticles successfully. PLURONIC F127, F68
solutions and other low MW emulsifiers, like Cremophor EL and Vitamin-E
TPGS, were also tested, but unstable emulsions resulted in large aggregated
particles.
Table 4 shows the characteristics of nanoparticles prepared using
PLGA-PEG (Mn--S3kDa) and PLGA (Mn-15kDa) and various emulsifiers
(1% w/v).
54
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
Table 4. Characteristics of biodegradable nanoparticles prepared by the
emulsification method using PLGA-PEG5k (Mn ¨83kDa) and PLGA (Mn
¨15kDa) and representative emulsifiers (1% w/v).
Polymer Emulsifier Emulsifie Diameter Div/Dm
[nm] potential
MW [Da] [mV]
DSS 444 136 5 -5.5 0.5 3.9
CHA 430 115 11 -3.7 0.4 5.1
CTAB 364 77 3 -4.6 0.7 5.6
Saponin 1.8k 108 1 -7.0 0.7 10
SE 540 97 3 -4.2 0.3 6.8
TWEEN
1.2k 156 7 -3.8 0.3 3.5
PLGA- TWEEN
1.3k 152 6 -4.2 0.3 6.8
PEG5k 80
F127 12.5k 169 8 -2.4 0.2 4.2
F68 8.4k 162 5 -3.3 0.3 4.2
TPGS 1.5k 204 7 -4.8 0.3 5.6
Cremopho
2.1k 232 4 -3.5 0.1 3.6
PVA 25k 156 8 -2.90.3 40,000
PEMA 400k 185 6 -42 1.6 23,000
PVA 25k 175 5 -2.6 1.0 19,000
PLGA
CHA 430 144 6 -72 2.2 41,000
Ratios of the ensemble average diffusion coefficients in water (D)
5 compared to in mucus (D.) at a time scale of 1 s.
To evaluate the effect of polyethylene glycol molecular weight (PEG
MW) on mucus-penetrating property of nanoparticles prepared by the
emulsification, CHA was selected as the representative low MW strong
emulsifier. PLGA-PEG nanoparticles with different PEG MWs at
10 approximately 6wt% PEG content were prepared in 0.5% CHA solution. In
order to achieve overall 6wt% PEG content for PLGA-PEGlOk
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
nanoparticles, blends of PLGA-PEGlOk (2L6 wt%) and PLGA15k were
utilized.
Results
Properties of nanoparticles prepared from PEG of various molecular
weights (-6wt% PEG content) are shown in Table 5.
Table 5. Characteristics of biodegradable nanoparticles prepared using PEG
of various MWs (-6wt% PEG content) by the emulsifcation method.
PEG Diamete -potential PEG [F/F*] [5]
MW r [tun] [nalT] density [11
[kDal
100nm2)
124 6 -2.3 1 0.1 6.7 3.0 9.6
5 107 3 -4.2 0.3 13.9 3.3 4.4
2 128 1 -12 0.9 26.2 2.5 5.0
1 134 5 -181 1.2 45.0 2.3 7.7
[a] PEG density [11 indicates the number of PEG molecules per 100 nm2. The
10 surface PEG content was quantified by IHNMR of nanoparticles in D20.
[b] Ratio of PEG density to full surface coverage [Fir]. Full surface
coverage [F*1 indicates the theoretical number of unconstrained PEG
molecules required to fully coat a 100 nm2 surface. ([F/F*]<1 indicates
mushroom regime with low surface PEG density, whereas >1 represents
brush regime with high surface PEG density)
Properties of nanoparticles prepared from various concentrations of
CHA and PLGA-PEG5k containing 6wt% PEG are shown in Table 6.
56
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
Table 6: Characterization of biodegradable nanoparticles using different
concentration of emulsifier (MA) prepared by the emulsification method.
PLGA-PEG5k containing 6wt% PEG was used.
Emulsifier ljw/v Voi Diameter (-potential
[nm] [my]
1 115 10 -3.7 0.4 5.1
0.5 107 3 -4.2 0.3 4.4
0.1 142 9 -3.5 0.6 4.1
0.01 125 6 -5.1 0.5 4.3
Example 3: Preparation of Drug Encapsulated Nanoparticles
Materials and Methods
Curcumin was selected as a model hydrophobic drug which was
dissolved with polymer in DCM. The procedure was similar to that for
preparation of unloaded nanoparticles. The prepared curcumin-nanoparticles
can be visualized in mucus because of curcumin's intrinsic fluorescence.
BSA was used as a model hydrophilic drug because it is
representative of large molecule biologics. BSA-FITC and BSA (10% ratio
of BSA-FITC) were dissolved in 0.2mL 16% w/v aqueous solution at 37 C.
This solution was added to lmL of 100mg/m1PLGA-PEG5k in DCM
solution during probe sonication (30% amplitude, 1mM with is pulse) in the
ice-water bath. The resultant W/O primary emulsion was immediately added
to a second water phase (5mL 1% saponin solution) under sonication (20%
amplitude for 2 min). The double emulsion was transferred to another 40 mL
1% saponin solution with magnetic stirring for 3 hours. Nanoparticles were
filtered through 1 um syringe filer, washed and collected by centrifugation.
BSA-FITC allowed the possibility to track BSA-loaded nanoparticles in
mucus.
Results
The target drug loading for curcumin nanoparticle and BSA
nanoparticle was 9.1% and 16.7%, respectively.
57
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
Example 4. Estimation of emulsification capability
Materials and Methods
PLGA-PEG5k (MW approximately 83kDa) was used as the model
polymer and was dissolved in DCM at 50mg/ml. A 0.5m1 solution of PLGA-
PEG5k in DCM was added to 5m1 aqueous phase containing 1% (w/v)
emulsifiers under sonication with 30% amplitude to prepare emulsion using
the same method described above. The formed emulsion was added to an
additional 20m1 1% emulsifier solution under magnetic stirring at 700 rpm
for 3 hours. The emulsification capability of each emulsifier was estimated
by its ability to prevent the formation of aggregated particles. Aggregated
particles were collected by centrifugation at 500g for 20min, and the
remaining nanoparticles in the supernatant were collected by centrifugation
at 30,000g for 25min. The weight ratio of nanoparticles to aggregated
particles was calculated, and used as the index to estimate the emulsification
capability of the emulsifier.
Diameter and surface charge
Diameter and 4-potential (surface charge) of nanoparticles were
measured using Zetasizer Nano ZS90. Nanoparticles were resuspended in
10mM NaCI solution. TEM samples were prepared by dropping a dilute
suspension of nanoparticle on a TEM grid and allowed to air dry. Particle
morphology was characterized using a H7600 transmission electron
microscope (Hitachi, Japan).
Encapsulation efficiency
The encapsulation efficiency of curcumin in nanoparticles was
measured by dissolving the freeze-dried nanoparticles in DMSO and
measuring the absorbance at 430nm using Biotek Synergy MX plate reader.
The drug content was determined by comparing to the curcumin calibration
curve (concentration range 0-50 pg/m1). Absorbance of blank nanoparticle in
DMSO at the same polymer concentration was subtracted. The encapsulation
efficiency of BSA-FITC was analyzed after alkaline digestion. A known
amount of freeze-dried nanoparticles underwent complete hydrolysis in 1M
sodium hydroxide. The resultant solution was analyzed using Biotek Synergy
IVD( plate reader at 490nm excitation wavelength and 525nrn emission
58
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
wavelength. Standard solutions containing the same amount of polymer and
increasing amounts of BSA-FITC at the same processing condition were
prepared. The amount of BSA in the nanoparticles was determined by
comparison to the BSA-FITC calibration curve.
Drug loading (DL) and encapsulation efficiency (EE) were calculated
as follows:
Weight of drug
DL
______________________________________ x100% Weight of nanoparticles
Experimental drug loading
EE (%) = _________________________________ x100%
Target drug loading
Results
The results for various emulsifiers are shown in Table 7.
Table 7: The encapsulation of model hydrophobic drug (curcumin) and
model hydrophilic drug (BSA) in both MPP (CHA and saponin as
emulsifier) and CP (PVA as emulsifier) using PLGA-PEG5k (6wt% PEG)
Formulation DL [Vo] EE [ /0] Diameter c-potential Dw/Dm
Lb) [nm] [mV]
PLGA- 4.5 49 156 12 -5.1 0.5 6
PEG5k/CHA
(curcumin)
PLGA- 4.3 47 151 11 -3.3 1.1 2400
PEG5k/PVA
(curcumin)
PLGA- 11.4 68 164 1 -4.5 0.4 36
PEG5k/Saponin
(BSA)
PLGA- 11.5 69 218 22 -2.20.8 5100
PEG5k/PVA
(BSA)
59
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
[a] Drug loading (DL%) represents the weight content of drug in
nanoparticles.
rbl Drug encapsulation efficiency (EE%) represents the ratio of final drug
loading in comparison to the theoretical drug loading.
Quantification of surface polyethylene glycol (PEG) density
The surface PEG density on nanoparticles was determined by 1H
NMR using Bruker 400 REM instrument at 400 MHz. Relaxation time was
set at 10s, and ZG at 90 . Nanoparticles with different PEG content were
directly prepared in 0.5% CHA D20 solution and suspended in D20 with
A known weight of PEG 5kDa (Sigma, St Louis, MO) homopolymer
in D20 with 1% 3-(trimethylsilyI)-1-propanesulfonic acid, sodium salt was
serially diluted to different concentration to set up the calibration curve
for
A 0.2m1 solution of nanoparticles in D20 was lyophilized and
weighed. By assuming all surface PEG chains were full length of PEG 5kDa,
the surface PEG density was calculated as the number of PEG molecules per
[r] = (vf,EG x 6.02 x1023) 47t(D12)2x 100
WNp/dNp /4/37r(D/2)3
where WNp is the total mass of nanoparticles, dNp is the density of
density of polymer, 1.21g/m1 for PLGA), and D is the particle diameter as
measured by the dynamic light scattering.
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
Full surface mushroom coverage [F*] is the number of unconstrained
PEG molecules occupying 100 nm2 of particle surface area. In order to
deteamine [F*], the surface area occupied by a single PEG chain was
estimated. Using random-walk statistics, a single PEG chain occupies an area
at the interface given by a sphere of diameter e:
4=-0.76m0.5 [A]
where m is the molecular weight of the PEG chain. The surface area
occupied by one PEG molecule can be determined from (e/2)2. Thus PEG
5kDa has an unconstrained molecule sphere with diameter of 5.4nm, and
occupies a surface area of 22.7 nm2. Therefore, the number of PEG
molecules to fully cover 100 rim2 surface area, [F*], is 4.4.
[17F*] can be used as an index to measure the PEG density on the
nanoparticle surface, where the values <1 indicates low PEG density where
PEG molecules are in a mushroom conformation; whereas values>1 indicate
high PEG density where PEG molecules are in a brush-like conformation.
Similarly, [F*] for PEG 10kDa, 2 kDa and 1 kDa is 2.2, 11 and 22,
respectively. The results are shown in Table 2 above.
Table 8 show the PEG surface density of PLGA-PEG nanoparticles
with different PEG contents. Surface PEG level was detected by 1H NMR in
D20 as compared to a standard DSS (1 wt%). The total PEG content in
nanoparticles was measured by 1H NMR in CDC13 as compared to a
standard TMS (1 wt%). N/A, not applicable.
61
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
Table 8. PEG surface density of PLGA-PEG nanoparticles with
different PEG contents
Target PEG Total PEG PEG content PEG surface [ F/F*1 [1']
content content in on NP density [I]
(wt%) the whole surface (chains/
NP (wt%) (wt%) 100nm2) [a]
25 13.010.3 12.911.0 29.712.9 6.710.7
7.410.1 7.210.2 19.4.11.3 4.410.3
8 6.010.3 6.010.3 16.4 1.6 3.710.4
5 3.710.1 3.7 0.2 10.410.2 2.410.04
3 2.510.1 2.610.1 6.510.2 1.510.05
2 1.410.4 1.410.02 3.310.1 0.76 0.02
0 N/A N/A N/A N/A
Ea] PEG density [1] means the calculated number of PEG molecules per 100
5 nm2 by assuming that all PEG chains on surface are full length of PEG
5kDa.
tbl PEG density/full surface coverage [17F*1. Full mushroom coverage [p]
means the number of unconstrained PEG molecules per 100 nm2. ( < 1
indicates mushroom coverage with low PEG density, whereas > 1 represents
brush regime; when the value >>1 represents a dense brush regime with
10 very high PEG density).
Data (mean SD) are the average of at least three different batches of
samples.
The surface PEG density an, the number of PEG chains per 100
nm2) was calculated and compared with full surface mushroom coverage
arl, the number of unconstrained PEG molecules per 100 nm2). PLGA-
PEG3% nanoparticles showed a surface PEG content of 2.6wt% with density
of 6.5 PEG/100nm2, equal to [F]/[F*]-1.5, which rendered PLGA-PEG3%
with brush conformation of surface PEG coating. High dense brush
conformation of PEG coating (nipp-3) was achieved at PEG surface
density higher than 10 PEG/100nm2 (PLGA-PEG5%).
62
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
By dissolving the freeze-dried PLGA-PEG nanoparticles in NMR
solvent CDC13, the total PEG content within nanoparticles by NMR was
measured and it was found that the total PEG contents in nanoparticles (both
surface PEG and the PEG embedded within nanoparticle cores) was very
close to the surface PEG contents, as shown in Table 5. Almost all the PEG
chains in the PLGA-PEG nanoparticles prepared by the emulsification
method were detected on the particle surface. The emulsification method
involved the evaporation of organic solvent (dichloromethane) from the
emulsion droplets and the followed solidification of polymer cores. The slow
evaporation of organic solvent provides enough time for hydrophilic PEG
chain to diffuse and assemble at the surface of nanoparticles, which resulted
in the high partition ratio of PEG to the surface. However, there is
significant
loss of PEG during the preparation of nanoparticles by the emulsification
method, and the PEG loss ratio can be as high as 50% for PLGA-PEG25%
nanoparticles.
Similar to previous reports, the loss of PEG may be due to the
formation of micelles by the low molecular weight portion of PLGA-PEG in
the copolymer, which have higher PEG content and higher hydrophilicity.
This part of very small sized particles containing higher PEG content
polymers cannot be collected after centrifugation and washing steps, which
can be confirmed from the increased average molecular weight of polymer
after the formation of nanoparticles in comparison to the raw polymer,
measured by gel permeation chromatography. PLGA-PEG10% nanoparticles
(117 nm) prepared by nanoprecipitation method (solvent diffusion method)
in a control experiment showed 6.5wt% total PEG content in the nanoparticle
and only 89% of PEG chains were detected at surface (equal to 5.8wt%
surface PEG content).
Example 5. Mucus penetrating tracking of nanoparticles
Materials and Methods
Human cervical vaginal mucus (CVM) was collected. Briefly,
undiluted cervicovaginal secretions from women with normal vaginal flora
were obtained using a self-sampling menstrual collection device following a
protocol approved by the Institutional Review Board of the Johns Hopkins
63
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
University. The device was inserted into the vagina for 60s, removed and
placed into a 50m1 centrifuge tube and centrifuged at 1000rpm for 2 min to
collect the secretions.
The tracking of fluorescently labeled nanoparticles in fresh human
cervicovaginal mucus (CVM) was performed. Briefly, 0.6 pi of
nanoparticles at suitable dilution was added to 20 il mucus within a custom-
made chamber slide and incubated at room temperature for 1 hour prior to
microscopy. The trajectories of nanoparticles in CVM were recorded by
using multiple particle tracking (MPT). 20s movies were captured at a
temporal resolution of 66.7ms using a silicon-intensified target camera (VE-
1000, Dage-MTI) mounted on an inverted epifluorescence microscope
equipped with 100x oil-immersion objective (N.A., 1.3). Tracking movies
(20s) were analyzed using MetaMorph software (Universal Imaging,
Glendale, WI).
Time averaged mean square displacement (MSD) and effective
diffusivity for each particle were calculated as a function of time scale:
<Ar2(T)>¨[x(t+ )-x(t)}2+[y(t+ t )-y(012
where x and y represent the nanoparticle coordinates as a function of
time and t is the time lag.
Curcumin-loaded nanoparticles and FITC-BSA-loaded nanoparticles
were tracked in human CVM in the same manner using the fluorescence
from either encapsulated curcurnin or BSA-FITC. Particle penetration into a
mucus layer was modeled using Fick's second law and diffusion coefficients
obtained from tracking experiments.
Results
The comparison of transport of human CVM of PLA-PEG and PCL-
PEG nanoparticles containing CHA and PVA prepared by emulsification is
shown in Figures la-h. Figures la and lb show representative trajectories of
PLA-PEG and PCL-PEG nanoparticles containing CHA and PVA. Figures
le and ld are graphs showing ensemble-averaged geometric mean square
displacements (<MSD>) as function of time scale. Figures le and if are
graphs showing the distributions of the logarithms of individual particle
effective diffitsivities (Deff) at a time scale of 1 s. Figures 1g and lb are
64
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
graphs showing the estimated fraction of particles capable of penetrating a
physiological 30ttm thick mucus layer over time. Data represent three
independent experiments with? 120 nanoparticles tracked for each
experiment. Error bars are presented as s.e.m. This data shows
immobilization of nanoparticles made using PVA and rapid mucus
penetration for nanoparticles made using a low MW emulsifier, CHA, with
effective diffusivities similar to those measured for PLGA-PEG5k
nanoparticles.
The effect of PEG molecular weight on transport rate of MPPs in
CVM is shown in Figures 2a and 2b. Figures 2a and 2b show the effect of
PEG MW on transport rate of MPP in human cervicovaginal mucus. Figure
2a is a graph showing the ensemble-averaged geometric mean square
displacement <MSD> as a function of time scale. Figure 2b is a graph
showing the distributions of the logarithms of individual particle effective
diffusivities (Deft) at a time scale of 1 s. Particles were prepared with the
emulsification method using PLGA-PEG (6wt% PEG). Data represent three
independent experiments with? 120 nanoparticles tracked for each
experiment. Error bars are presented as s.e.m. These particles all rapidly
penetrated mucus (see also Table 5).
The nanoparticle surface charge was inversely proportional to the
PEG MW and varied from -18 mV (1 kDa) to -2.3 mV (10 kDa). The surface
PEG density [11 (number of PEG per 100 nm2) measured by 1H NMR
decreased as PEG MW increased. However, the ratio [F/r][11] of surface
PEG density to the theoretical PEG density required for the formation of a
brush-like PEG coating [PI] was greater than 2 (Table 5), regardless of PEG
MW, indicating the presence of a dense brush-like coating of PEG on the
surface of PLGA-PEG(1-10 kDa)/CHA nanoparticles.
Figures 3a-3c shows the transport rates of curcumin and BSA loaded
MPPs and conventional particles (CPs). Figure 3a is a graph showing the
ensemble-averaged geometric mean square displacement <MSD> as a
function of time scale. Figure 3b is a graph showing the distributions of the
logarithms of individual particle effective diffusivities (Deft) at a time
scale
of 1 s. Figure 3c is a graph showing the estimated fraction of particles
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
predicted to be capable of penetrating a 30 um thick mucus layer over time.
Data represent three independent experiments with > 120 nanoparticles
tracked for each experiment. Error bars are presented as s.e.m. Curcumin
and BSA-loaded nanoparticles rapidly diffused in mucus at rates only 6 and
36-fold slower than in water at il s, respectively (Figure 3a). In contrast,
nanoparticles prepared with PVA were immobilized in CVM (Figure 3b),
with transport rates more than 2,000-fold slower than in water.
PLGA nanoparticles without PEG coating were completely
immobilized within mucus with diffusivities 38,000 times slower than the
diffusivities of same sized nanoparticles in water. The presence of PEG
surface coating on nanoparticles significantly improved their diffusion
through the highly viscoelastic mucus, PLGA-PEG3% with surface PEG
density of 6.5 PEG/100nm2 showed increased Dw/Dm value up to 142.
Further increasing the surface PEG density up to 10.4 PEG/100nm2, PLGA-
PEG5% nanoparticles were only 17-fold slower than their diffusion in water.
More than 90% of the nanoparticles were diffusive when surface PEG
density was higher than 16.4 PEG/100nm2 (PLGA-PEG8%). Further
increase of the surface PEG density likely will not significantly improve the
particle diffusivity within mucus, since a surface density of 16.4
PEG/100nm2 is already capable to efficiently shield the binding of mucus
components. Approximately 50-70% nanoparticles of PLGA-PEG8%, 10%
and 25% were able to penetrate physiological 30um thick mucus layer within
60 mins, are much higher rates than PLGA-PEG5%, PLGA-PEG3% (dense
coating), PLGA-PEG2%(low coating) and PLGA (no coating).
Example 6: Stability of Nan oparticles in Mucus.
Materials and Methods
The stability of nanoparticles in mucus by minimizing the adhesive
interaction between particles and mucus components is an important criterion
for their application as mucus-penetration drug carriers in vivo. The change
in nanoparticle size in the presence of mein as the indication of mucin
binding was studied to determine the stability of nanoparticles with different
PEG surface density at the presence of mucin. Mucin extracted from bovine
submaxillary gland was chosen as a model mucin because mucin is the main
66
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
component of mucus and mucin from bovine submaxillary gland shares
similarity with human CVM in both structure and physiological properties.
Nanoparticles were incubated with mucin solution (10mg/nil) and the
change of particle size over time was monitored.
Results
PLGA-PEG nanoparticles with PEG surface density >16.4
PEG/100nrn2 were stable in mucin solution retaining their hydrodynamic
diameter during the whole 3 hour incubation, and at these PEG surface
densities the PEG coatings were in high dense brush conformation
Gridir*1>3). In contrast, PLGA-PEG5% nanoparticles with surface density
of 6.5 PEG/100nm2 showed approximately 5% increase in particle diameter
after the incubation with mucin solution even only for 5 mins, and the PEG
surface density on these PLGA-PEG5% nanoparticles already resulted in a
brush PEG coating ([11/[Fl>1). Therefore, brush PEG coatings alone are
not enough to completely shield the mucin binding. There was a progressive
increase in particle size with decreased PEG surface density from brush
conformation to mushroom conformation. Without PEG coating, PLGA
nanoparticles exhibited a dramatic size increase from 109 2 mn to 207 9 nm
within 5 min of incubation in mucin.
Figure 4a is a schematic illustrating the influence of surface PEG
coverage ([F/F1 ) on mucus penetration of nanoparticles. The upper panels
show the preparation of PLGA-PEG nanoparticles with surface PEG coating
at increasing coverage. As surface PEG coverage increases, PEG regime
changes from mushroom (neighboring PEG chains do not overlap, [UP] <1,
Figure 4a), to brush (neighboring PEG chains overlap, 1<[FX*1<3, Figure
4b), to dense brush (pri>3, Figure 4c). The middle panels illustrate how
PEG coverage determines the muco-adhesive interaction after mucus
exposure. At low PEG coverage ([F/F1 <1), mucin fibers strongly adhere to
nanoparticle core. At middle PEG coverage (1<[F/F*]<3), mucin fibers still
can partially absorb to the nanoparticle core. At high ([FX*]>3) PEG
coverage, the nanoparticle cores were completely shielded by the bioinert
PEG corona resulting in no absorption of mucin to nanoparticles. The lower
panels show that nanoparticles with low PEG coverage are immobilized in
67
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
mucus, nanoparticles with middle PEG coverage are hindered or even
immobilized in mucus, nanoparticles with high and very high PEG coverage
are able to rapidly penetrate mucus.
Example 7: Effect of osmolarity of particle solution on distribution
and retention of nanoparticle in vaginal and colon mucosal tissue.
Mucus penetrating nanoparticles (MPP) that avoid being adhesively
trapped by the mucus layers present on mucosal surfaces were used to study
this effect at mucosal surfaces. Extremely dense coatings of low molecular
weight (5kDa) polyethylene glycol (PEG) were covalently attached to the
surface of fluorescent 100nm carboxyl-modified polystyrene (PS) particles to
produce mucuspenetrating PS-PEG nanoparticles. Uncoated nanoparticles
("conventional particles", or "CP") stick to mucins. CP do not penetrate the
mucus layers well and, instead, aggregate in the lumen of flash-frozen whole
mouse colonic and vaginal tissue. However, MPP penetrated the mucus
barrier all the way to the underlying epithelium, producing a continuous
"layer" of particles in both mouse rectal and vaginal tissue. The great
absorptive capacity of mucosal surfaces could rapidly "suck" the MPPs, but
not CPs, through the mucus layers if the particles are administered in a hypo-
osmolar solvent, like pure water. Particle administration in a hypoosmolar
solution, such as ultrapure (UP) water, causes fluid absorption by the tissue
underlying the mucus layers in order to reach osmotic equilibrium, thus
drawing in MPP by convection.
There have been recent reports detailing the negative side effects of
administering highly hyperosmolar formulations used for vaginal and rectal
delivery, which can cause significant toxicity and epithelial erosion (Fuchset
al. J Infect Dis 195, 703-710 (2007); Lacey et al. Int J STD AIDS 21, 714-
717 (2007)). However, mildly hypoosmolar fluids have not been shown to
have the same toxicity profile.
Materials and Methods
The distribution of fluorescent 100 urn mucus-penetrating PEGylated
polystyrene particles on cross-sections of flash-frozen whole colon tissue
administered in either (A) 1X PBS or (B) ultrapure water was examined.
68
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
Tissue was excised immediately after administration and was stained with
DAN to show cell nuclei.
Distribution of fluorescent 100 rim mucus-penetrating PEGylated
polystyrene particles on cross-sections of flash-frozen whole vaginal tissue
administered in either (A) 1X PBS or (B) ultrapure water was also examined.
Tissue was excised immediately after administration and was stained with
DAPI to show cell nuclei.
Fluorescence of whole mouse vaginal tracts and colorectal tissue after
initial administration of fluorescent nanoparticles in either UP water
(hypoosmolar) or PBS (isoosmolar) was then assessed.
To evaluate nanoparticle retention, 5 RI, of red fluorescent CPs or
MPPs were administered intravaginally. Whole cervicovaginal tracts were
obtained at 0, 2,4, and 6 h and placed in a standard tissue culture dish. For
each condition and time point, n> 7 mice were used. Fluorescence images
of the tissues were obtained using the Xenogen IVIS Spectrum imaging
device (Caliper Life Sciences). Quantification of fluorescent counts per unit
area was calculated using the Xenogen Living Image 2.5 software.
Results
MPP quickly begin to line the vaginal and colorectal epithelium when
administered in hypoosmolar solution.
The percentage of MPP (PSPEG) and CP (PS) retained in the mouse
vaginal tract over time after administration in UP water was measured. After
6h, 57% of MPP and 7% of CP remain in the CV tract.
MPP were retained in the vaginas of mice at much higher amounts
for at least 6 hours.
Biodegradable MPP containing FITC intravaginally was administered
in UP water. As a comparison, FITC in the standard isoosmolar placebo gel,
hydroxyethlycellulose (HEC), was administered. After 24 h, the vaginal
tissue was excised and flattened between two glass slides. The hypotonically
delivered MPP appeared to fully coat the epithelium, whereas the FITC was
sparsely distributed. MPP dramatically improved the epithelial distribution
of an otherwise poorly distributed entity.
69
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
Example 8: Distribution of MPPs in Vaginal Tissues as a function of
Osmolarit-y
The studies in Example 7 demonstrated that MPP that do not adhere
to mucus are capable of rapidly diffusing through human and mouse
cervicovaginal mucus (CVM), leading to penetration deep into the more
slowly cleared mucus layers in the algae, coating the entire vaginal surface
and residing in the vagina longer than conventional mucoadhesive
nanoparticles (CP), published by Ensign, et al Sci Trans!' Med 4, 138ral 79
(2012).
One key to the improved vaginal distribution and retention by MPP
was administering the nanoparticles in a hypotonic solution. When delivered
in a hypotonic solution, MPP rapidly accumulated on the entire vaginal
surface, arriving there much more rapidly than expected based on diffusion
alone. When fluid is pressure-induced to flow through the mucus gel, MPP
flow through the mucus along with the flowing fluid (i.e., by solvent drag).
Studies were conducted to determine if a similar effect would occur if drugs
and MPP were delivered into the vagina in hypotonic formulations. This
study investigated hypotonic vaginal delivery of free drug as well as by MPP
to determine whether hypotonic delivery might provide improved
distribution, retention, and protection.
Materials and Methods
Animal model
Female 6-8 week-old CF-1 mice were purchased from Harlan
(Indianapolis, IN). Mice were housed in a reverse light cycle facility (12 h
light/12 h dark), to enable selection of mice in a naturally cycling estrus
state. The mouse vagina during the estrus phase of the estrous cycle is most
similar to the human vagina. Barrier properties to nanoparticles in estrus
phase mouse mucus closely mimic the barrier properties to nanoparticles in
human CVM. Thus, mice in estrus phase, as determined visually by the
appearance of the vaginal introitus, were used for all distribution and
retention studies. Mice used for vaginal HSV-2 protection and susceptibility
studies were given a subcutaneous flank injection of 2.5 mg Depo-Provera
(Pharmacia & Upjohn Company, New York, NY) in 100 j.tL phosphate-
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
buffered saline (PBS) 7 days prior to experiments. This treatment is
commonly used to increase susceptibility to vaginal HSV-2 infection. All
experimental protocols were approved by the Johns Hopkins Animal Care
and Use Committee.
Nanoparticle preparation and characterization
Fluorescent, carboxyl(COOH)-modified polystyrene (PS)
nanoparticles 100 nm in diameter were purchased from Molecular Probes
(Eugene, OR). To produce MPP, PS particles were covalently modified with
5 kDa amine-modified PEG (Creative PEGworks, Winston Salem, NC) as
previously described by Nance et al Sc! Transl Med 4, 149ra1 1 9 (2012).
Particle size and .-potential were determined by dynamic light scattering and
laser Doppler anemometry, respectively, using a Zetasizer Nano ZS90
(Malvern Instruments, Southborough, MA). Size measurements were
perfoluted at 25 C at a scattering angle of 90 . Samples were diluted in 10
mM NaC1 solution (pH 7) and measurements performed according to
instrument instructions. A near neutral -potential was used to confuni PEG
conjugation, and particles were tested for mucus-penetrating ability in human
CVM as previously described by Lai et al, Proe Nati Acad Sc! USA 104,
1482-1487 (2007) and Wang etal. Angew Chem Int Ed Engl 47, 9726-9729
(2008). These particles were previously shown to rapidly penetrate estrus
phase mouse vaginal mucus. The osmolality of solutions was measured
using a Wescor Vapro vapor pressure osmometer.
Drug and nanoparticle distribution in the vagina
Doxorubicin (NetQem, Durham, NC) was dissolved at 1 mg/ml
concentration in either PBS (isoosmolar with respect to blood) or ultrapure
water (hypoosmolar). For 1 liter of 1X PBS, 800 ml of distilled water; 8 g of
NaCl; 0.2 g of KCI; 1.44 g of Na2HPO4; 0.24 g of KH2PO4; actjust the pH to
7.4 with HC1, add distilled water to a total volume of 1 liter.
Doxorubicin was vaginally administered both isoosmotically and
hypoosmotieally to mice in two different conditions. The "non-ambulatory"
group was anesthetized with an intraperitoneal injection of Avertin working
solution (prepared according to Johns Hopkins ACUC guidelines) and
71
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
remained supine for 1 hr prior to tissue collection. The "ambulatory" group
was anesthetized with fast-acting, inhalable isoflurane, such that the mice
immediately awoke and were ambulatory for 10 min prior to tissue
collection. The vaginal tissues were then collected, sliced open
longitudinally, flattened, and clamped between two glass slides sealed shut
with super glue. This procedure completely flattens the tissue, exposing the
surfaces that were infolded from the lumen. Tissues were imaged on a
epifluorescence microscope (Nikon E6100) at 2x magnification.
Doxorubicin is fluorescent (ex/ern 470/590). Untreated control tissues were
imaged to ensure that the fluorescent signal from Doxonibicin was well
above the tissue autofluorescence. The low magnification captured large
portions of the tissue, so only 2-3 images were needed to observe the entire
tissue surface. The images were Ihresholded to draw region of interest
boundaries around the fluorescent signal, and then the area covered
quantified using Image.1 software. An average percentage coverage was
determined for each mouse, and these values were averaged over groups of n
= 5 mice.
To capture the distribution of MPP due to immediate fluid absorption
dynamics, 20 ul of either isoosmolar (PBS) or hypoosmolar (ultrapure water)
MPP solution was administered vaginally. The higher volume of solution
helped ensure that the lumen would be filled with fluid, and the particles
were diluted (0.01% w/v) such that concentration gradients would be visually
evident. The mice were anesthetized with isoflurane, and sacrificed
immediately after particle administration. The vaginal tissue was quickly
excised and flash-frozen in Tissue-Tek O.C.T. Compound. Transverse
sections were obtained at various points along the length of the tissue using
a
Leica CM-3050-S cryostat. The thickness of the sections was set to 6 um to
achieve single cell layer thickness. The sections were then stained with
ProLong Gold antifade reagent with DAPI to visualize cell nuclei and retain
particle fluorescence. Fluorescent images of the sections were obtained with
an inverted epifluorescence microscope (Zeiss Axio Observer). For MPP
distribution with varying solution osmolality, particle solutions (0.08% w/v)
were prepared from varying ratios of PBS and ultrapure water. Mice were
72
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
anesthetized with isoflurane, and 5 ul of particle solution was administered
vaginally. After 10 min, tissues were collected, flash-frozen, sectioned, and
stained following the procedures outlined for observing fluid absorption
dynamics. In order to quantify MPP vaginal tissue coverage, mice were
anesthetized with isoflurane, and 5 IA of nanoparticie solution was
administered vaginally. Within 10 min, tissues were excised, sliced open
longitudinally, and then flattened as described for drug distribution
experiments. Control tissues were imaged to ensure that the fluorescent
signal was well above the tissue autofluorescence. Tissues were imaged at
10x magnification using an inverted epifluorescence microscope (Zeiss Axio
Observer), and 8 images per tissue were acquired. The coverage was
quantified as previously outlined for drug distribution experiments.
Drug and nanopartiele retention in the vagina
Doxorubicin was dissolved at a concentration of 1 mg/ml in
phosphate buffered saline ("PBS") (isoosmolar with respect to blood) or
ultrapure water (hypoosmolar). Mice were anesthetized with an
intraperitoneal injection of Avertin prior to intravaginal administration of 5
pi of Doxorubicin solution. The mice remained supine for 10 min to ensure
that solution "drip out" would not affect the retention measurement. Then,
the whole cervicovaginal tracts were excised and placed in a standard tissue
culture dish. Fluorescence images of the tissues were obtained using the
Xenogen IVIS Spectrum imaging device (Caliper Life Sciences). To account
for potential differences in Doxorubicin solution fluorescence, vials of both
isoosmolar and hypoosmolar Doxorubicin solutions were included in the
image. The ratio of the intensity of the two solutions was used to normalize
the tissue fluorescence for each group. Quantification of fluorescent counts
per unit area was calculated using the Xenogen Living Image 2.5 software.
The average for the isoosmolar and hypoosmolar groups was normalized to
the isoosmolar group.
Red fluorescent MPP were suspended in either PBS (isoosmolar) or
ultrapure water (hypoosmolar) at 0.2% (w/v). Mice were either anesthetized
with an intraperitoneal injection of Avertin ("non-ambulatory") or by
inhalation of isoflurane ("ambulatory") as described previously for drug
73
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
distribution experiments. Five 111 of either isoosmolar or hypoosmolar MPP
solution was administered intravaginally. After 1 h for non-ambulatory
mice, or 10 min for ambulatory mice, whole cervicovaginal tracts were
excised and placed in a standard tissue culture dish. Fluorescence images
were taken and quantified as described for drug retention. As a reference
point for MPP retention, 5 Ill of MPP solution was carefully pipetted into the
vagina after the whole cervicovaginal tract was already removed and placed
in a tissue culture dish. This approach was used for MPP (but not
Doxorubicin), because the nanoparticles do not penetrate the tissue; therefore
there is no potential effect from differential tissue penetration on the
fluorescent signal. The retention was then calculated as a percentage of the
average reference tissue signal.
HSV-2 infection mouse model
Mice received 20 ml of 10 mg/ml acyclovir monophosphate dissolved
in either PBS (isoosmolar) or ultrapure water (hypoosmolar) immediately
before use. This drug was shown to give partial protection in a mouse model
of vaginal HSV-2 infection. Mice were dosed either 1 min or 60 min prior to
viral inoculum. Mice were then challenged with 10 gl of inoculum
containing HSV-2 strain G (ATCC #VR-724, 2.8 x 107 TCID50 per m1). For
protection studies, HSV-2 was diluted 10-fold with Bartel's medium to
deliver 10 ID50, a dose that typically infects 85-90% of control mice. For
osmotic-induced susceptibility tests, virus was diluted 10-fold with Bartel's
medium and further diluted 10-fold in either Bartel's medium (isoosmolar)
or deionized water (hypoosmolar) to the ID, a dose that infects half of the
mice. Mice were assessed for infection three days later after inoculation by
culturing a PBS vaginal lavage on human foreskin fibroblasts (Diagnostic
Hybrids, MRHF Lot #440318W). In this model, input (challenge) virus is no
longer detectable in lavage fluid if it is collected more than 12 h after the
challenge.
Statistics
The Wilcoxon rank-sum test was used to compare data sets. This test
is non-parametric, and more appropriate in situations where a Gaussian
74
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
distribution cannot be assumed. For HSV-2 infection studies, statistical
significance was determined using Fisher's exact test, two-tailed
distribution.
Results
Effect of tonicity on vaginal drug distribution
When the mice were non-ambulatory (supine for 1 h), only15% of the
vaginal tissue area was covered by Doxorubicin administered in isoosmolar
solution, whereas 88% was covered when administered in hypoosmolar
solution (Figure 5A). When the mice were ambulatory for 10 mins prior to
tissue collection, the isoosmolar solution delivered Doxorubicin to 25% of
the vaginal surface area, whereas the hypoosmolar solution delivered it to
86% of the area (Figure 5B). The isoosmolar solution only delivered the
drug to the vaginal surfaces facing the lumen, not the surfaces contained
within the collapsed vaginal folds, thus producing the pattern of "stripes"
with the unexposed tissue appearing black. In contrast, the hypoosmolar
solution distributed the Doxorubicin to the entire vaginal surface.
Effect of tonicity on vaginal drug retention
Isoosmolar and hypoosmolar Doxorubicin solutions were
administered intravaginally to anesthetized mice to avoid any effect of
solution leakage. After 10 min in the supine position, the entire reproductive
tract was excised and analyzed quantitatively with fluorescence imaging.
After only 10 mm, the relative fluorescent signal of Doxorubicin
administered in hypoosmolar solution was half that of Doxorubicin
administered in isoosmolar solution (Figure 6).
Effect of tonicity on prevention of vaginal HSV-2 infection
The enhanced distribution of hypotonically administered drug was
tested at short times and how the reduced retention at longer times would
affect the efficacy of a vaginally administered drug. Acyclovir
monophosphate (ACVp), a moderately protective drug that provides partial
protection when administered 30 mm prior to viral inoculum in a mouse
model of vaginal HSV-2 infection was used since it would likely reveal any
benefit of improved distribution. Similar to Doxorubicin, ACVp is water
soluble and acts intracellularly. First, it was ensured that hypotonic fluid
did
not increase susceptibility to infection by administering the ID50 dose of
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
virus (typically infects ¨50% of the mice) suspended in either isotonic or
hypotonic solution. When virus was administered in either isotonic or
hypotonic solution, 60% (9/15) mice were infected. This control experiment
indicated changes in infection rate were due to the presence of the drug and
of mice were infected when ACVp was administered isotonically, and 31%
(14/45) of mice were infected when ACVp was administered hypotonically
Effect of osmotically-driven convection on vaginal nanoparticle
20 distribution
Hypotonic delivery of free drug led to improved distribution in the
vaginal tract, but osmotically-induced absorption of fluid may cause drugs
for which the vaginal epithelium is permeable to be removed by solvent drag.
In contrast, the vaginal epithelium is essentially impermeable to
25 nanoparticles, and, if they are mucus-penetrating, osmotic flow delivers
them
to the epithelial surface. MPP, capable of penetrating vaginal mucus, coat the
entire vaginal surface within 10 min after being delivered in a hypotonic
solution. Even if delivered in hypotonic fluid, mucoadhesive nanoparticles
(CP) aggregate in the lumenal mucus layers and are not transported through
30 vaginal mucus to the vaginal epithelium by osmotically-induced
convection.
The dependence on tonicity of osmotically-driven distribution of MPP
immediately after administration was determined. By freezing vaginal
76
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
tissues immediately after MPP administration, one was able to take a "snap-
shot" of the initial particle distribution dynamics.
When MPP were administered in isotonic solution, the nanoparticles
were found distributed throughout the lumen, but when delivered in
hypotonic solutions, a gradient in particle concentration was apparent, with
MPP being concentrated at the surface of the vaginal epithelium. From the
surface distribution of MPP, it is evident that hypotonically-induced fluid
flow resulted in MPP being rapidly drawn to the vaginal surface, without
absorption across the epithelium.
Effect of tonicity on vaginal nanoparticle retention
It was hypothesized that, in contrast to free dug administered in
hypotonic solution, vaginal retention of MPP would improve with hypotonic
delivery. Since it was anticipated that fluid leakage would play a role in
nanoparticle retention, both non-ambulatory and ambulatory conditions were
compared. In the case of non-ambulatory mice (supine for 1 h), 69% of MPP
administered in isotonic solution and 83% of MPP administered in hypotonic
solution were retained (Figure 8A). It is likely that the 1 h period allowed
for fluid absorption and removed gravitational effects, reducing leakage.
Although a higher percentage of MPP were retained when administered in
hypotonic solution, the difference was not statistically significant.
However, when the mice were ambulatory, there was a significant
decrease in the retention of MPP administered in isotonic solution. After 10
mm of ambulation, only 22% of MPP administered in isotonic solution were
retained compared with 75% of MPP administered in hypotonic solution
(Figure 8B). It appears that the rapid delivery of MPP to the vaginal surface
led to the increased retention since much of the fluid in the vagina is
rapidly
discharged during ambulation..
Effect of osmolality on vaginal nanoparticle distribution
It is well known that tonicity can strongly affect cells, and recent
evidence highlights the toxicity of strongly hypertonic gels on both vaginal
and rectal epithelia, particularly with repeated exposure. Hypotonic solutions
may also cause toxicity. To avoid potential toxic effects it was investigated
whether modest levels of hypotonicity might still improve particle
77
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
distribution in the vagina. Within 10 min of administration, MPP in
hypotonic solutions covering a 10-fold range (20-220 mOsm/kg) delivered
MPP to the vaginal surface). In contrast to an isotonic solution (294
mOsm/kg) that left MPP particles distributed throughout the vaginal lumen
with few being drawn to the epithelial surface, a modestly hypotonic solution
(220 mOsm/kg) caused rapid transport to the epithelial surface. Also, there
was a trend toward increase vaginal coverage with increasing hypotonicity:
In the most hypotonic solution (20 mOsm/kg), MPP coated 88% of the
vaginal epithelium after 10 min, whereas only 60% of the vaginal surface
was coated with MPP administered in 294 mOsm/kg solution (Figure 9). At
all tonicities tested, MPP reached a greater fraction of the epithelial
surface
than muco-adhesive (CP) particles, and the minimally hypotonic solution
(220 mOsm/kg) delivered particles to 76% of the vaginal surface, a
significant increase compared with 60% coverage by the isotonic solution
(294 mOsm/kg).
In conclusion, the studies investigating the use of hypotonic solutions
for convection-enhanced drug delivery to the vagina showed that although
hypotonic delivery of Doxorubicin improved the vaginal distribution, the
drug was absorbed through the epithelium, reducing vaginal retention. In
contrast, it was found that hypotonic delivery of mucoinert mucus-
penetrating nanoparticles (MPP) improved both distribution and retention. In
addition, it was found that even minimally hypotonic delivery significantly
improved the vaginal distribution of MPP. The results indicate that
hypotonic formulations are more effective for drug delivery to the vagina
than the traditional hypertonic formulations, and that MPP delivered
hypotonically offer significant promise for non-toxic sustained drug delivery
to the entire vaginal surface.
Although there was improved distribution of drug in hypotonic
solution, fluid absorption could potentially lead to rapid removal of the drug
by fluid transport through the vaginal epithelium. Using acyclovir
monophosphate (ACVp), a trend toward improved protection by ACVp in
hypotonic solution vaginally administered immediately before HSV-2 virus
was demonstrated. The improved protection is likely due to the increase in
78
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
vaginal coverage by drug administered in hypotonic solution. In contrast,
when HSV-2 was administered 1 h after the drug, the protection by ACVp
administered in hypotonic solution was significantly decreased compared to
ACVp in isotonic solution. Drug absorption across the epithelium with
osmotically-induced fluid flow led to drug clearance and decreased
protection after 1 h. MPP offer a way to achieve improved distribution of
drug by hypotonic delivery since nanoparticles accumulate on the surface of
the vaginal epithelium and MPP containing ACVp demonstrated better
protection than 10-fold higher concentration of free drug when administered
vaginally 30 min prior to HSV-2 virus. MPP are immediately drawn to the
vaginal epithelium when administered in a minimally hypotonic solution.
Fluid absorption and secretion can also affect vaginal retention. It
was previously demonstrated that in humans that the leakage rate of vaginal
gels increased linearly with increasing hypertonicity (Zeitlin et al.
Contraception 68, 139-155 (2003)). In this case, retention was reduced by
osmotically-induced fluid secretion leading to product leakage. This
indicates that hypotonic products would cause fluid absorption and reduced
leakage, and might thereby improve vaginal retention. It was found that this
was not necessarily true for drugs, unlike MPP, that can be absorbed through
the vaginal epithelium. MPP, by penetrating into the more slowly cleared
mucus layers in the deep vaginal folds, are retained longer than
mucoadhesive CP. As shown by this study, MPP are better retained in the
vaginal tract of ambulatory mice when administered in hypotonic solution as
compared to administration in isotonic solution by reducing vaginal leakage.
the results indicate that a hypotonic gel formulation containing MPP would
likely enhance both drug distribution and retention in the human vagina.
Example 9: Comparison of Effect of Osmolarity on Particle Uptake in
Colon
Materials and Methods
Studies were conducted as described in Examples 7 and 9 comparing
distribution of MPP in the mouse colon in solution with varying tonicity..
Studies compared particle uptake in the colon with 20 mOsm, 260 mOsm,
350 mOsm, 450 mOsm, 860 mOsm, and 2200 mOsm solutions. The only
79
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
reason one can obtain advective transport to the epithelium with
hyperosmolar solutions is if they were hyperosmolar with Na.
Distribution of various sizes of CP and MPP after rectal
coadministration to mice with TNBS-induced colitis was also determined.
Fluorescent images of flattened colonic tissue after hypotonic rectal
administration of solutions containing a mixture of CP (red) and MPP
(green) of various sizes (100 nm, 200 nm, 500 nm) were analyzed.
Transverse colonic cryosections of 200 TIM CP and MPP (cell nuclei stained
blue with DAPI) were also prepared.
Results
The effective osmolality of the colon appears to be between 400-530
mOsm/kg, above blood plasma osmolality (-300 mOsm/kg). This higher
range is supported by Billich and Levitan, T Clinical Invest, (1969). Vehicles
with an osmolality of 400 mOsm/kg and below provide improved
distribution of MPP on the colon tissue surface. .
Example 10: Determination of Toxicity of Hypoosmotic MPP
Formulations
Recent studies indicate that in response to certain vaginal products,
the vaginal epithelium can secrete immune mediators that may enhance
susceptibility to sexually transmitted infections. It has also been
established
that other conditions, such as pre-term labor, are associated with
reproductive tract inflammation. Thus, it is important that a vaginal product
not induce such an immune response, particularly after repeated dosing.
Hyperosmolal formulations previously have been demonstrated as toxic to
the vaginal and rectal epithelium, which can negate the protective or
therapeutic benefits of administered drugs. Accordingly this study was
conducted to insure that hypoosmolal formulations do not cause toxicity
when administered to the mucosal epithelium.
Materials and Methods
Seven daily treatments with purely hypotonic (-20 mOsm/kg) fluids
(carrying Pluronic F127 or MPPs) and standard isoosmolar
hydroxyethylcellulose were compared to no treatment. Hypertonic gel
(vehicle containing 20% glycerol, used in clinical trials). A hypotonic gel
CA 02863632 2014-08-01
WO 2013/110028
PCT/US2013/022387
formulation (HEC gel with 20% increased water content to offset water
absorption) containing MPP was compared to a conventional hypertonic gel
formulation (HEC containing 20% glycerol, a standard glycerol
concentration used for vaginal gel formulations) based on vaginal
crosssectional images.
Twenty ill, of each test agent was administered intravaginally to the
DP mouse model once-a-day for seven days. HEC gel and N9 were provided
by T. Moench (Reprotect), and TFV vehicle gel was kindly provided by C.
Dezzutti (University of Pittsburgh). On the eighth day, each mouse was
lavaged twice with 50 }IL of PBS. Each lavage sample was diluted with an
additional 200 uL of PBS and centrifuged to remove the mucus plug.
Supernatant (200 uL) was removed and split into 50 jiL for each of the four
(IL-113, IL-la, INF-a, and 1L-6) Quantikine ELISA kits (R&D Systems).
ELISAs were conducted per the manufacturer's instructions.
Results
Seven daily treatments with purely hypotonic (-20 mOsni/kg) fluids
(carrying Pluronic F127 or MPPs) and standard isoosmolar
hydroxyethylcellulose do not cause an increase in vaginal cytokines (IL-1
alpha/beta) compared to no treatment. Hypertonic gel (vehicle containing
20% glycerol, used in clinical trials) caused a significant increase in these
vaginal cytokines. A hypotonic gel formulation containing MPP was
compared to a conventional hypertonic gel formulation based on vaginal
crosssectional images. It appears as though the vaginal distribution and
retention of MPP after 6 h is improved with the hypotonic (81% retained
after 6 h) gel (HEC gel with 20% increased water content to offset water
absorption) as compared to the hypertonic (--20% retained after 6 h) gel
formulation (HEC containing 20% glycerol, a standard glycerol
concentration used for vaginal gel formulations).
81
